

CONVENING NOTICE

Combined General Shareholder's meeting (Ordinary and Extraordinary)

Friday, June 24, 2022 at 9 a.m. (Paris time)
Hôtel Intercontinental
2 rue Scribe
75009 Paris - France



erytech

CONTENTS

| | |
|--|----|
| AGENDA..... | 2 |
| HOW TO ATTEND THE GENERAL MEETING? | 4 |
| BOARD OF DIRECTORS REPORT | 13 |
| DRAFT RESOLUTIONS PROPOSED TO THE COMBINED GENERAL SHAREHOLDERS' MEETING OF JUNE 24, 2022 | 31 |
| SUMMARY OF CURRENT FINANCIAL DELEGATIONS | 57 |
| PROFESSIONAL REFERENCES OF PROPOSED DIRECTORS | 61 |
| REQUEST FOR ADDITIONAL DOCUMENTS AND INFORMATION | 66 |
| STATUTORY AUDITORS' REPORTS | 67 |
| SPECIAL REPORTS OF THE BOARD OF DIRECTORS..... | 67 |

COMBINED GENERAL SHAREHOLDERS' MEETING OF JUNE 24, 2022

AGENDA

INFORMATION: COVID-19

In the context of the COVID-19 epidemic, the Company may have to modify the terms and conditions of participation in the Shareholders' Meeting of June 24, 2022, in accordance with health and/or legal and regulatory requirements. Consequently, shareholders are invited to consult regularly the section dedicated to the Shareholders' Meeting on the Company's website (www.erytech.com), which may be updated to specify the definitive terms and conditions of participation in this Shareholders' Meeting.

In addition, in consideration of the spread of the COVID 19 virus, the Board of Directors recommends that shareholders exercise the highest degree of caution in this context and that they vote by mail or give their proxy to the Chairman rather than attend the meeting in person.

The Company has taken all measures to facilitate remote voting so that shareholders can also vote without physically attending the General Meeting by remote voting means (postal voting or proxy), using the voting form provided for this purpose available on ERYTECH's website (www.erytech.com) or by internet on the secure voting platform Votaccess.

Resolutions within the competence of the Ordinary General Meeting

1. Approval of the financial statements for the year ended December 31, 2021
2. Approval of the consolidated financial statements for the year ended December 31, 2021
3. Allocation of results for the year
4. Approval of the special report of the statutory auditors on regulated agreements and commitments
5. Approval of the information mentioned in article L.22-10-9 I of the French commercial code concerning the executive corporate officers' compensation for the year ended December 31, 2021
6. Approval of the elements of total compensation and benefits of all kinds paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer
7. Approval of the elements of total compensation and benefits of all kinds paid or allocated for the year ended December 31, 2021, to Jean-Paul KRESS, Chairman of the Board
8. Approval of the compensation policy for executive corporate officers
9. Approval of the compensation policy for Board Members
10. Renewal of the term of office of Jean-Paul KRESS as Director
11. Renewal of the term of office of Gil BEYEN as Director
12. Renewal of the term of office of Philippe ARCHINARD as Director
13. Renewal of the term of office of Luc DOCHEZ as Director
14. Ratification of the appointment by cooptation of Sven ANDRÉASSON as Director
15. Renewal of the term of office of Sven ANDRÉASSON as Director
16. Renewal of the term of office of KPMG S.A as co-statutory auditor
17. Non-renewal of the term of office of SALUSTRO REYDEL as alternate statutory auditor
18. Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on July 27, 2021
19. Authorization for the Company to buy back its own shares

Resolutions within the competence of the Extraordinary General Meeting

20. Authorization for the Board of Directors to reduce the Company's share capital by canceling the treasury shares held by the company
21. Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued immediately or in the future by the Company, with existing shareholders' preferential subscription rights maintained
22. Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued immediately or in the future by the Company, with shareholders' preferential subscription rights waived by public offering other than the public offerings referred to in section 1° of article L.411-2 of the French monetary and financial code
23. Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued by the Company immediately or in the future, with preferential subscription rights waived, by public offering referred to in section 1° of article L.411-2 of the French monetary and financial code
24. Authorization to the Board of Directors, in the case of an issue, with existing shareholders' preferential subscription rights waived by public offering, of common shares of the Company and/or securities convertible to common shares to be issued by the Company, to set the issue price in accordance with the terms and conditions set by the general meeting, of up to 10% of the share capital per year
25. Authorization for the Board of Directors, in the case of a capital increase with existing shareholders' preferential subscription rights maintained or waived, to increase the number of shares to be issued
26. Delegation of authority to the Board of Directors, with shareholders' preferential subscription rights waived, to increase the Company's share capital through an issue reserved for certain categories of investors
27. Delegation of authority to the Board of Directors, with shareholders' preferential subscription rights waived, to increase the Company's share capital through an issue reserved for certain categories of investors as part of an "At-the-market" or "ATM" equity financing program
28. Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued by the Company in the event of a public exchange offer initiated by the Company, with shareholders' preferential subscription rights waived
29. Authorization for the Board of Directors to issue with existing shareholders' preferential subscription rights waived, common shares and/or securities convertible to common shares to be issued, to be used as payment for in-kind contributions to the Company consisting of equity securities or other securities convertible to shares
30. Delegation of authority to the Board of Directors to increase the capital by incorporating reserves, profits or premiums
31. Delegation of authority to the Board of Directors to carry out capital increases reserved for employees participating in an Erytech Pharma group savings plan, with shareholders' preferential subscription rights waived
32. Authorization for the Board of Directors to award bonus shares, existing or to be issued, with existing shareholders' preferential subscription rights waived, to corporate officers or employees of the Company or related companies
33. Authorization for the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies in the Erytech Pharma group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options
34. Authorization for the Board of Directors to issue share subscription warrants, with existing shareholders' preferential subscription rights waived, to corporate officers or employees of the Company or Erytech Pharma group companies
35. Powers for carrying out formalities

HOW TO ATTEND THE GENERAL MEETING?

Shareholders have the following options to attend the General Meeting:

1. To attend the General Meeting in person at the above-mentioned place
2. Vote remotely by post or by internet on the secure voting platform *Votaccess*; or
3. Give a proxy to any individual or legal entity of their choice, in accordance with applicable laws and regulations, or give a proxy to the Chairman of the Shareholders' Meeting. The Chairman will then vote on their behalf in favor of the adoption of the draft resolutions presented or approved by the Board of Directors and against the adoption of all other draft resolutions.

In accordance with article R. 22-10-28 of the French Commercial Code, any shareholder who has already voted by mail, sent a proxy, requested an admission card or a certificate of participation, will no longer be able to choose another method of participation in the Meeting. These participation methods are specified below.

PRELIMINARY FORMALITIES TO BE CARRIED OUT IN ORDER TO ATTEND THE GENERAL SHAREHOLDERS' MEETING

General Shareholders' Meetings shall be composed of all the shareholders, regardless of the number of shares they hold.

In accordance with article R.22-10-28 of the French Commercial Code, shareholders are required to have provided proof of share ownership either by registering their shares in their name or in the name of their intermediary duly registered to act on their behalf, two business days before the Meeting (i.e., by June 22, 2022, at 00:00 Paris time):

- Either in the registered share account held for the Company by its authorized agent Société Générale Securities Services,

- Either in the bearer share accounts held by their securities intermediary.

The registration of shares in the bearer share accounts held by an intermediary mentioned in Article L.211-3 of the French Monetary and Financial Code must be evidenced by a certificate of participation issued by the intermediary, where applicable by electronic means appended to the vote form or proxy form or to the request for an admission card drawn up in the name of the shareholder or on behalf of the shareholder represented by the registered intermediary.

METHODS OF ATTENDANCE AT THE GENERAL MEETING

I. Shareholders wishing to attend the General Meeting in person

Shareholders wishing to attend the General Meeting in person must obtain an admission card, which they may request as follows:

Request for an admission card by mail

Registered shareholders may request an admission card by returning the completed and signed form attached to the notice of meeting in the T envelope enclosed with the notice of meeting or by mail to Société Générale Securities Services - Service des Assemblées - CS 30812, 44308 Nantes Cedex, France. Registered shareholders who have not received their admission card by the date of the General Meeting may nevertheless participate in the meeting by providing proof of their identity.

Bearer shareholders shall ask the authorized intermediary who manages their securities account to send them an admission card. Bearer shareholders wishing to attend the General Meeting and who have not received their admission card by the second business day preceding the meeting, i.e. June 22, 2022, must present a certificate of participation issued by their authorized financial intermediary in accordance with the regulations and a proof of identity.

Request for an admission card by electronic means

Shareholders wishing to attend the Shareholders' Meeting in person may also request an admission card by electronic means in the following manner:

Registered shareholders may request an admission card on the secured Votaccess platform by logging on to the website www.sharinbox.societegenerale.com using their usual login and password, their Sharinbox access code, which is recalled on the single form attached to the notice of meeting received by post or in the e-mail sent to them. The login details can be re-sent by clicking on "Get your login details" on the home page of the website. After logging in, the registered shareholder must follow the instructions given on the screen to request an admission card.

Bearer shareholders will be able to connect with their usual identifiers and access codes to the Internet portal of their Securities Account Holder to access the Votaccess Internet site and then follow the procedure indicated on the screen to request their admission card. Only bearer shareholders whose account holder has subscribed to the Votaccess website will be able to request an admission card via Internet. The admission card will be available according to the procedure indicated on the screen.

The Votaccess platform for the Shareholders' Meeting will be open as of June 3, 2022. The possibility of requesting an admission card via Internet before the Shareholders' Meeting will end on June 23, 2022, at 3:00 p.m., Paris time. In order to avoid any possible congestion of the Votaccess platform, shareholders are strongly advised not to wait until the day before the Shareholders' Meeting to enter their instructions.

II. Shareholders unable to participate by attending the Meeting in person

Shareholders may vote by mail or by proxy, using the voting form provided for this purpose and returning it by mail, or vote electronically via the secure voting platform Votaccess.

Correspondence voting by mail

Registered shareholders must return, using the T envelope that will have been sent to them in the convening notice, their duly completed and signed postal voting form to Société Générale Securities Services, Service des Assemblées, CS 30812, 44308 Nantes Cedex 03.

Bearer shareholders must return their duly completed and signed single postal voting form to their authorized financial intermediary who manages their securities account. This intermediary will prove their status as a shareholder and return the form to Société Générale Securities Services.

The Company informs bearer shareholders that they can download the form from the Company's website

but must go through their account holder to return their instruction to the Company, which must be accompanied by the certificate issued by the financial intermediary, which will thus provide proof of the holder's status as a shareholder. The Company will not process voting forms received alone (without a certificate from the account holder).

These forms will only be taken into consideration if they are duly completed and signed and received by Société Générale Securities Services by mail at Société Générale Securities Services - Service des Assemblées - CS 30812, 44308 Nantes Cedex, France, at least three days before the date of the Meeting (i.e. June 21, 2022).

Electronic voting by correspondence

Shareholders also have the possibility to send their voting instructions, before the General Meeting, on the Votaccess website, under the conditions below.

Registered shareholders can access Votaccess by logging on to the website www.sharinbox.societegenerale.com using their usual login and password, their Sharinbox access code, which is mentioned on the single form attached to the notice of meeting received by post or in the e-mail sent to them. Once connected, registered shareholders must follow the instructions given on the screen to access the Votaccess platform and vote.

Bearer shareholders will be able to connect with their usual identifiers to the Internet portal of their Securities Account Holder with their usual access codes to access the Votaccess Internet site and then follow the procedure indicated on the screen to vote. It is specified that only bearer shareholders whose account holder institution has subscribed to the Votaccess site will be able to vote online.

The Votaccess platform for the Shareholders' Meeting will be open as of June 3, 2022. The possibility of voting by Internet before the Shareholders' Meeting will end on June 23, 2022, at 3 p.m. (Paris time). In order to avoid any possible congestion of the Votaccess platform, shareholders are strongly advised not to wait until the day before the Shareholders' Meeting to enter their instructions.

Appointment and revocation of a proxy

Shareholders who do not attend the Meeting may be represented by a proxy given to the Chairman of the Meeting, to their partner, to the partner with whom a civil solidarity pact has been concluded, to another shareholder or to any other individual or legal entity of their choice, in accordance with the conditions set forth in Articles L. 225-106 and L. 22-10-39 of the French Commercial Code. A shareholder who has chosen to be represented by a proxy of his or her choice may notify this appointment or revoke it:

By post, using the voting form sent either directly to registered shareholders (using the T envelope enclosed with the notice of meeting), or by the holder of the securities account for bearer shareholders and received by Société Générale Securities Services, Service des assemblées générales, CS 30812, 44 308 Nantes Cedex, France, three days before the General Meeting;

By electronic means, by connecting, for registered shareholders, to the website www.sharinbox.societegenerale.com, and for bearer shareholders to the Internet portal of their securities account holder to access the Votaccess website, according to the procedures described in the section "Voting by mail by electronic means", no later than Wednesday, June 23, 2022, at 3:00 p.m., Paris time.

It is reminded that written and signed proxies must indicate the name, first name and address of the shareholder as well as those of the proxy. In accordance with article R. 225-79 of the French Commercial Code, shareholders may notify Société Générale Securities Services of the revocation of a proxy in the same form as that used for its appointment. It is specified that for any proxy given by a shareholder without indication of a proxy, the Chairman of the General Meeting will issue a vote in accordance with the recommendations of the Board of Directors. For bearer shareholders, the form must be accompanied by the certificate of participation issued by the authorized intermediary.

REQUEST FOR INCLUSION OF ITEMS ON THE AGENDA OR DRAFT RESOLUTIONS

One or more shareholders meeting the conditions set out in Article R.225-71 of the French Commercial Code may request that items or draft resolutions be included on the agenda. These items or draft resolutions are included in the agenda of the Shareholders' Meeting and brought

to the attention of the shareholders under the conditions determined by the regulations in force.

The request for inclusion of items or draft resolutions on the agenda of the General Meeting must, in accordance with the legal and regulatory provisions in force, be sent to the registered office

(ERYTECH Pharma, 60 avenue Rockefeller 69008 Lyon, France), by registered letter with acknowledgement of receipt or electronically to the address legal@erytech.com by May 30, 2022, at the latest.

This request must be accompanied by a certificate of account registration justifying the holding of the minimum required capital referred to in article R.225-71 of the Commercial Code. The request for the inclusion of an item on the agenda must be justified. The request for the inclusion of draft resolutions is accompanied by the text of the draft

WRITTEN QUESTIONS

In accordance with Article R.225-84 of the French Commercial Code, any shareholder has the right to ask questions in writing. Written questions that shareholders may ask before the Shareholders' Meeting must be sent to the Company's registered office (ERYTECH Pharma, 60 avenue Rockefeller 69008 Lyon, France), by registered letter with return receipt requested addressed to the Chairman of the Board of Directors, or by e-mail to legal@erytech.com, no later than the fourth

SHAREHOLDERS' RIGHT OF COMMUNICATION

The documents that should be made available to shareholders in connection with this General Meeting will be available at the Company's registered office, 60 avenue Rockefeller 69008 Lyon, under the conditions provided for by the applicable legal and regulatory provisions.

All documents and information relating to the Shareholders' Meeting and mentioned in article R.22-10-23 of the French Commercial Code will be available on the Company's website at the following address: <https://erytech.com/fr/> as from the twenty-first day preceding the Shareholders' Meeting (i.e. June 3, 2022).

resolutions, together with a brief explanatory statement.

In addition, consideration by the Shareholders' Meeting of items or draft resolutions submitted by shareholders is subject to the submission by the authors of the request of a new certificate proving the registration of the shares in the same accounts on the second business day preceding the Shareholders' Meeting (i.e., June 22, 2022, at midnight, Paris time).

business day preceding the date of the Shareholders' Meeting (i.e., June 20, 2022, at 00:00 a.m., Paris time). In order to be considered, these written questions must be accompanied by a certificate of registration either in the registered share accounts held by the Company or in the bearer share accounts held by an intermediary mentioned in Article L. 211-3 of the French Monetary and Financial Code.

All the information and documents mentioned in articles R. 225-81 and R. 225-83 of the French Commercial Code are attached to this notice.

The full name of the Directors and general managers and, where applicable, the indication of the other companies in which these persons exercise management, administrative or supervisory functions are contained in section 3.1.1.2.2 of the 2021 Universal Registration Document.

SUMMARY OF ERYTECH PHARMA'S SITUATION IN 2021

FACTS CHARACTERIZING THE FINANCIAL YEAR

Operating activities

In the Phase 2 study in acute lymphoblastic leukemia (ALL), conducted by the Nordic Organization of Pediatric Hematology and Oncology (NOPHO)

Since 2017, the Company supported a Phase 2 clinical trial initiated and sponsored by investigators of the Nordic Society of Pediatric Hematology and Oncology, or NOPHO. This trial evaluated the safety and pharmacological profile of eryaspase in ALL patients, who developed hypersensitivity reactions to prior asparaginase treatment or silent inactivation to pegylated L-asparaginase. In December 2020, positive results from the trial were presented at the American Society of Hematology Annual Meeting. The trial was conducted at 21 clinical sites in the Nordic and Baltic countries of Europe and enrolled 55 patients. The main objectives of the trial were the activity and safety of eryaspase. Both objectives were met. In July 2021, the Company announced a pre-BLA meeting with the U.S. Food and Drug Administration, or FDA after which the Company confirmed its intention to submit a BLA, subject to successful completion of remaining activities. Also in July 2021, eryaspase was granted Fast Track Designation by the FDA for the treatment of ALL patients who have developed hypersensitivity reactions to *E. coli*-derived asparaginase. The BLA application is now almost completed, and the Company is planning for submission once the FDA has finalized its review of the remaining information requests.

rESPECT, Phase 1 investigator-sponsored trial in first-line pancreatic cancer

In pancreatic cancer, the Company is supporting an investigator-sponsored clinical trial, or IST called rESPECT. This study is evaluating the safety and tolerability of the combination of eryaspase with modified FOLFIRINOX in the first-line treatment of pancreatic cancer. The Georgetown Lombardi Comprehensive Cancer Center is the sponsor of this trial. The first patient was enrolled in January 2021 and, following evaluation of treatment response after two treatment cohorts, the Company announced a maximum tolerated dose determination in October 2021. Interim data, presented at ASCO GI in January 2022, confirmed the acceptable safety profile in the trial and showed encouraging clinical activity. Out of the twelve patients enrolled, ten patients have been evaluated for response. They all achieved disease control; five patients had an objective response and five achieved stable disease. The trial will continue enrolling up to approximately 18 patients. Reporting of data is expected in the third quarter of 2022.

TRYbeCA-1, pivotal Phase 3 clinical trial in second-line advanced pancreatic cancer

In 2018, the Company initiated a pivotal Phase 3 clinical trial of eryaspase for the treatment of second-line advanced pancreatic cancer patients. Patient enrollment in this trial referred to as the TRYbeCA-1 trial, began in September 2018 in Europe. The Company has obtained clinical trial authorizations in the United States and from 11 European Union countries and have conducted the clinical trial at close to 90 clinical sites. In April 2020, the FDA, granted eryaspase Fast Track Designation as a potential second-line treatment for patients with metastatic pancreatic cancer. Eryaspase has also received orphan drug designation for pancreatic cancer

in both the United States and Europe. The Company completed the patient enrollment in the TRYbeCA-1 trial in December 2020. A total of 512 patients participated in the trial, slightly above the target enrollment of 482 patients. ERYTECH reported top-line final results of the TRYbeCA-1 trial on October 25, 2021. These results show that the study did not meet the primary efficacy endpoint of overall survival. Nevertheless, a preliminary analysis of the results of a subgroup of patients indicated a potential efficacy signal for patients treated with eryaspase in combination with FOLFIRI chemotherapy cocktail.

TRYbeCA-2, randomized Phase 2 clinical trial in triple-negative breast cancer (TNBC)

In the fourth quarter of 2018, the Company launched TRYbeCA-2, a proof-of-concept Phase 2 clinical trial in TNBC in the European Union. Following the publication of the negative results of the TRYbeCA-1 study, and with a goal of reducing costs and preserving cash flow, it has been announced in November 2021 that recruitment of new patients in this study will be stopped. The results from the patients enrolled prior to the end of recruitment in the TRYbeCA-2 trial to date are expected to be reported in the third quarter of 2022.

Financing

Raise of \$30 million in a registered offering in April 2021

On 29 April 2021, the Company announced having entered into definitive agreements with several healthcare focused institutional and accredited investors for the purchase and sale of 1,034,483 units (“Units”), each Unit consisting of four ordinary shares in the form of American Depositary Shares (each an “ADS”) and three warrants, each to purchase one ordinary share (each a “Warrant”), in a registered direct offering to specified categories of investors, described below. The subscription price for one Unit was \$29.00 (€24.03), corresponding to \$7.25 (€6.01) per ADS and associated 0.75 warrant. Each ADS represents the right to receive one ordinary share, €0.10 nominal value of the Company. The Warrants have an exercise price of €7.50 (\$9.05) per share and are immediately exercisable upon issuance and will expire two years from the issuance date.

Raise of \$7.85 million in a registered offering in December 2021

On 14 December 2021, the Company announced that it had entered into a definitive agreement with Armistice, a healthcare focused institutional and accredited investor, for the purchase and sale of 769,608 units (“Units”), each Unit consisting of four ordinary shares in the form of American Depositary Shares (each an “ADS”) and three warrants, each to purchase one ordinary share (each a “Warrant”), in a registered direct offering to specified categories of investors, described below. The subscription price for one Unit was \$10.20 (€9.04), corresponding to \$2.55 (€2.26) per ADS and associated 0.75 warrant. Each ADS represents the right to receive one ordinary share, €0.10 nominal value of the Company. The Warrants have an exercise price of €2.83 (\$3.19) per share and are immediately exercisable upon issuance and will expire two years from the issuance date.

SIGNIFICANT EVENTS SINCE THE BEGINNING OF THE 2022 FINANCIAL YEAR

ERYCEV™, novel red blood cell vesiculation technology

The Company presented its red blood cell vesiculation technology at the 24th Meeting of the European Red Cell Society (ERCS) in April 2022. RBC-derived extracellular vesicles are formed naturally during senescence and storage of mature RBCs and are a potentially attractive drug delivery system. Vesiculation of RBCs that have already been loaded with active therapeutic compounds utilizing the ERYCAPS® process, entails the potential of producing cargo-loaded RBC-derived extracellular vesicles for the development of novel therapeutic approaches.

U.S. cell therapy manufacturing facility sold to Catalent for a total consideration of USD 44.5 million

Under the terms of an asset purchase agreement between ERYTECH and Catalent, Catalent acquired ERYTECH's state-of-the-art commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, for a total consideration of \$44.5 million. ERYTECH's staff at the site of approximately 40 people have been offered employment by Catalent. The parties also agreed on the terms of a long-term supply agreement, under which Catalent will manufacture ERYTECH's lead product candidate eryaspase (GRASPA®) for clinical and commercial supply in the United States.

The Princeton facility is a 30,900 square foot modern manufacturing facility, designed with the flexibility to expand to support various cell therapy production requirements and capacities. Catalent intends to expand the Princeton site and leverage the experienced staff previously employed by ERYTECH to manufacture a broader portfolio of cell therapies. ERYTECH retained its manufacturing site in Lyon, France and its expertise and capabilities in manufacturing process science to continue innovating in cell therapy manufacturing.

PRESENTATION OF ECONOMIC AND FINANCIAL RESULTS

ERYTECH PHARMA SA

Revenues will amount to €892,049 in 2021 compared to €1,072,224 in 2020. This decrease is mainly due to a decrease in intra-group re-invoicing (Erytech Pharma Inc.).

Total operating revenues amount to €1,577,776 in 2021 compared to €1,496,033 for the previous year.

Operating expenses amounted to €57,708,964 in 2021 compared to €73,419,538 in the previous year. Other purchases and external expenses decreased by (€14,859,623), mainly in connection with the continuation of the TRYbeCA-1 pancreatic cancer clinical trial.

The operating result is a loss of (€56,131,188) in 2021, compared with (€71,923,505) in the previous year. Financial income will amount to (€3,828,148) in 2021, compared with (€2,615,074) in 2020. The increase in financial income in 2021 is mainly due to the rise in the value of the dollar against the euro, which generated a net foreign exchange gain in 2021 and a reversal of provisions for foreign exchange losses of €3,553,800.

Profit before tax and exceptional items for the year will be a loss of (€52,303,039) in 2021, compared with a loss of (€74,538,579) in the previous year. Exceptional items in 2021 amount to

(€8,773). The income tax item is an income of (€3,668,719) in 2021 compared to (€3,432,022) in 2020. It corresponds to the research tax credit.

Taking into account the above items, the net result for the year is a loss of (€48,643,094).

ERYTECH Group

The Group prepares its consolidated financial statements in compliance with IFRS standards and interpretations and presents its income statement by function. The Group does not generate any revenue given the stage of development of its products.

Considering that no research and development expense is capitalized before marketing authorization is obtained, the research tax credit linked to research programs is fully recognized under other income. Research tax credit amounted to €3,669 thousand in 2021.

In 2021, research and development costs totaled €45,100 thousand while general and administrative expenses totaled €15,595 thousand. Current operating income was therefore loss of €56,515 thousand and net interest income totaled a loss of €2,720 thousand in 2021.

Based on the above items, the Group recorded a net loss for the period in the amount of €53,797 thousand.

FINANCIAL RESULTS OF ERYTECH PHARMA S.A OVER THE LAST 5 YEARS

| | 31/12/2017 | 31/12/2018 | 31/12/2019 | 31/12/2020 | 31/12/2021 |
|--|--------------|--------------|--------------|--------------|--------------|
| Financial position at year end | | | | | |
| Share capital (in euros) | 1 793 756 | 1 794 004 | 1 794 004 | 2 005 756 | 3 101 855 |
| Number of shares issued | 17 937 559 | 17 940 035 | 17 940 035 | 20 057 562 | 31 018 553 |
| Number of bonds convertible into shares | – | – | – | – | – |
| Total income from operating activities (in euros) | | | | | |
| Revenue excluding VAT | 1 080 015 | 1 392 777 | 2 339 998 | 1 072 224 | 892 049 |
| Income before tax, amortization, and provisions | (30 299 689) | (30 304 925) | (55 403 129) | (71 321 454) | (52 804 529) |
| Income tax* | (3 186 956) | (4 374 728) | (3 913 289) | (3 432 022) | (3 668 719) |
| Income after tax, amortization, and provisions | (27 932 926) | (26 085 189) | (54 208 339) | (71 036 842) | (48 643 094) |
| Amount of profit distributed | – | – | – | – | – |
| Income from transaction limited to a single share | | | | | |
| Income after tax, but before amortization and provisions | (2,38) | (1,45) | (2,87) | (3,69) | (2,07) |
| Income after tax, amortization and provisions | (2,46) | (1,45) | (3,02) | (3,86) | (2,05) |
| Dividend paid for each share | – | – | – | – | – |
| Workforce | | | | | |
| Number of employees | 101 | 131 | 152 | 152 | 135 |
| Amount of total payroll expenses | 4 922 650 | 6 607 512 | 7 713 637 | 7 865 365 | 6 937 882 |
| Amount paid as employee benefits (social security, other benefits, etc.) | 2 740 109 | 3 493 329 | 3 765 277 | 4 093 063 | 3 573 678 |

BOARD OF DIRECTORS REPORT

The purpose of this report is to present the draft resolutions submitted to the General Meeting by the Company's Board of Directors. This report refers to the Universal Registration Document 2021, which has been filed with the French Financial Markets Authority (*Autorité des marchés financiers*) on April 27, 2022, under number D. 22-0367 and which can be consulted on the Company's website at the following address: <https://erytech.com/fr/> (Investors tab/AMF Regulated Information/Universal Registration Document). The prior notice relating to the General Meeting, provided for in article R.225-73 of the French Commercial Code, was published in the *Bulletin des Annonces Légales Obligatoires* of 18 May 2022, bulletin n° 59, announcement 2201825.

On the ordinary part of the General Assembly

Approval of the annual financial statements, the consolidated financial statements, and allocation of results (1st, 2nd, and 3rd resolutions)

The first two resolutions refer to the approval of the Company's financial statements, which show a loss of EUR 48,643,093.61, and the consolidated financial statements, which show a loss of EUR 53,796,953 for the fiscal year ended December 31, 2021.

The 3rd resolution relates to the allocation of results. You are requested to allocate the loss for the financial year ended December 31, 2021, amounting to EUR 48,643,093.61 in full to the "Share premium" account, which after allocation will amount to EUR 21,407,975.74.

Approval of the agreements and commitments mentioned in Article L.225-38 of the French Commercial Code (4th resolution)

In the fourth resolution, you are requested to take note of the conclusions of the Statutory Auditors' special report on regulated agreements and commitments referred to in Article L. 225-38 of the French Commercial Code. In this respect, you are informed that no new regulated agreements were concluded during the year ended December 31, 2021.

Compensation of the Executive Corporate Officers and Directors (5th to 9th resolutions)

The 5th resolution is, in compliance with article L. 22-10-34 I of the French Commercial Code, for the approval of the information mentioned in article L.22-10-9 I of the same code related to the compensation of the executive corporate officers as detailed in section 3.1.2.1.2 of the 2021 Universal Registration Document.

The 6th and 7th resolution are, in compliance with article L. 22-10-34 II of the French Commercial Code, for the approval of fixed, variable, and exceptional elements of total compensation and the benefits of any type paid during financial year ended on December 31, 2021, or allocated under the same year to Mr. Gil BEYEN, Chief Executive Officer and to Mr. Jean-Paul KRESS, Chairman of the Board, as detailed in section 3.1.2.1.1 of the 2021 Universal Registration Document.

The 8th resolution is, in compliance with article L.22-10-8 II of the French Commercial Code, for the approval of the compensation policy applicable to executive corporate officers as detailed in section 3.1.2.2.2 of the 2021 Universal Registration Document.

To date, Gil BEYEN, on account of his position as Chief Executive Officer and Jean-Paul KRESS on account of his position as Chairman of the Board are the only officers

concerned by this vote. The Deputy General Managers, Jérôme BAILLY and Eric SOYER, receive compensation under their employment contracts only, for their respective roles as Director of Pharmaceutical Operations and Chief Financial Officer/Chief Operating Officer, and therefore do not receive any compensation for their term of corporate office.

The 9th resolution is, in compliance with article L.22-10-8 II of the French Commercial Code, for the approval of the compensation policy applicable to Board Members as detailed in section 3.1.2.2.3 of the 2021 Universal Registration Document.

The Board of Directors, on the recommendation of the compensation and appointments committee has established the compensation policy applicable to executive corporate officers and board members and the compensation of each of them, as detailed in section 3.1.2.2 of the 2021 Universal Registration Document.

Composition of the Board of Directors (10th to 15th resolutions)

You are requested in the 10th to 13th resolutions, to renew the following terms of office as directors for a three-year term, that will end at the close of the Ordinary General Meeting of Shareholders to be held in 2025 to approve the financial statements for the year ending December 31, 2024:

- Jean-Paul KRESS, residing 50 Gray Street Boston MA 02116 (United States);
- Gil BEYEN, residing 96 South ST #4, Boston, MA 02111 (United States);
- Philippe ARCHINARD, residing 47 rue Professeur Deperet, 69160 Tassin-la-Demi-Lune (France);
- Luc DOCHEZ, residing 8 Klein Vilvoordestraat 3078 Meerbeek (Belgium).

In the 14th and 15th resolutions, you are invited to ratify the appointment by cooptation of Sven ANDRÉASSON, residing 3528 Reservoir Road NW, Washington D.C 20007 (United States), following his provisional appointment by the Board of Directors on 4 January 2022, and to decide on the renewal of his term of office as Director for a period of three years, which will expire at the end of the Ordinary Shareholders' Meeting to be held in 2025 to approve the financial statements for the year ending December 31, 2024.

The background and professional qualifications of each Director proposed for reappointment are presented below.

Terms of office of joint statutory and alternate auditors (16th and 17th resolutions)

You are requested in the 16th resolution to renew the terms of office for a six-year term of KPMG S.A, with its registered office located 2 Avenue Gambetta Tour Eqho, Paris la Défense 92066 Nanterre Cedex (France), registered under number 775 726 417 RCS Nanterre, as joint statutory auditor of the Company, that will end at the close of the ordinary general meeting of shareholders to be held in 2028 to approve the financial statements for the year ending December 31, 2027.

Following the entry into force of the law n°2016-1691 of December 9, 2016 (*Loi Sapin 2*), the appointment of one or several alternate auditors in order to replace the statutory auditor in the cases provided for by law is only required if the appointed statutory auditor is a natural person or a single member company (article L.823-1 paragraph 2 of the French Commercial Code). As the joint statutory auditors of the Company are legal and multi-partners entities, you are requested in the 17th resolution not to renew the terms of office of SALUSTRO REYDEL, with its registered office located Tour Eqho 2 Avenue Gambetta Paris la Défense 92066 Nanterre Cedex (France), registered under number 652

044 371 RCS Nanterre, as alternate auditor of the Company.

Approval of the regulations of the share subscription or purchase option plan (18th resolution)

We remind you that the General Shareholders' Meeting of June 25, 2021, authorized the Board of Directors, pursuant to Article L. 225-177 *et seq* of the French Commercial Code, to grant, to the benefit of employees and/or corporate officers, options for subscription or purchase of shares of the Company.

As required under Section 422 of the US Internal Revenue Code, to allow the issue of incentive stock option specified in the 2021 Options plan, for employees who are US residents for tax purposes, we indicate that the 2021 Options plan must be approved by the General Shareholders' Meeting of the Company within one year as from its adoption by the Board of Directors at its meeting on July 27, 2021.

Authorization granted to the Board of Directors to proceed with buying back Company shares (19th resolution)

The purpose of the 19th resolution is to renew the authorization granted to the Board of Directors by the Combined General Shareholders' Meeting of June 25, 2021, to buy back shares of the Company, that will expire at the end of a period of 18 months.

This delegation of authority to the Board of Directors, with the option to sub-delegate, would allow it to buy or have bought shares of the Company as part of the implementation of a share buyback program that cannot exceed 5 % of the amount of equity capital existing on the day of this General Shareholders' Meeting. The share buyback program will be framed within the following financial limits:

- **The maximum purchase price** may not exceed ten (10) euros per share, or its equivalent in foreign currency, with the

understanding that this maximum price may be adjusted in the event of capital transactions such as the capitalization of reserves and award of bonus shares, and/or the splitting or grouping of shares;

- **Maximum volume:** the Company shall refrain from purchasing beyond the maximum daily volume of shares authorized by laws and regulations in place at the time this authorization is used (currently, 25% of the average daily number of shares traded on the regulated Euronext Paris stock market).

The objectives of these share buybacks would be the following:

- the allocation of shares to employees or corporate executives of the Erytech Pharma Group;
- the stimulation of the market liquidity for the share by the intermediary of one or more investment services providers;
- the reduction of the capital of the Company by the cancellation of shares; and
- the allocation of shares to cover debt securities that are convertible or that can be exchanged against Company shares or any other type of securities giving access to shares of the Company, by conversion, presentation of a warrant, reimbursement or exchange.

This program would also be intended to allow the Company to trade in its shares in order to carry out any transaction authorized by law, or any market practice allowed by the market authorities, with the understanding that the Board of Directors cannot, unless there is prior authorization by the General Shareholders' Meeting, make use of this authorization in a public offering period initiated by a third-party targeting the shares of the Company, until the end of the offering period.

On the Extraordinary part of the General Assembly

Authorization to the Board of Directors to reduce the Company's share capital by canceling the treasury shares held by the Company (20th resolution)

Subject to the adoption of the 19th resolution on the authorization to be granted to the Board of Directors to proceed with the share buyback, you are asked to authorize the Board of Directors to proceed with the cancellation of all or part of the common shares of the company acquired as part of the share buyback program authorized by the 19th resolution or other share buyback programs authorized previously or subsequently, and to reduce the equity by the overall nominal amount of the shares thus canceled, limited to 10% of the capital of the Company by periods of 24 months.

The Board of Directors cannot, unless previously approved by the General Shareholders' Meeting, make use of this authorization starting from the deposit by a third-party of a public offering targeting the shares of the Company and until the end of the offering period.

Any positive difference between the purchase price and the nominal value of the common shares would be recognized in "issue premiums" or to any other available reserves item, including the legal reserve, limited to 10% of the capital reduction made.

The authorization thereby granted to the Board of Directors is valid for a period of 18 months from the date of this General Shareholders' Meeting.

"Financial" delegations of authority to the Board of Directors to issue of shares and/or other marketable securities convertible to the shares to be issued immediately or in the future by the Company, with or without the preferential subscription rights of the shareholders (21st to 30th resolutions)

To allow your Board of Directors to seize the opportunity of equity financing that would present to the Company, it is proposed to the General Shareholders Meeting, of June 24, 2022 to renew the financial delegations adopted by the General Shareholders' Meeting of June 25, 2021 in its 21st to 30th resolutions for a period of 26 months starting from the General Shareholders' Meeting, i.e., until August 24, 2024 (except for the delegation that would be granted by the 26th and 27th resolution for a period of 18 months, i.e., until December 24, 2023).

The renewal of all of these financial delegations is to allow the Company to have the flexibility and responsiveness necessary to allow it to strengthen its own equity and seize the strategic opportunities that arise by authorizing the Board of Directors to choose, depending on changes in market conditions and its financing needs, the most adequate resources for financing the Erytech Pharma Group, at the times and according to the methods that seem the most appropriate to it. The financial delegations that we are asking you to renew, could in particular enable us to implement different financing possibilities (including the issue of convertible bonds, the issue of shares carrying warrants, a capital increase with preferential subscription rights for shareholders or financing by way of an issue of common shares with the waiver of preferential subscription rights, including in the form of American Depositary Shares, primarily or only on the US market through an offering reserved for specific categories of persons). In this view, the Board of Directors proposes to the General Shareholders' Meeting to increase the ceilings adopted last year concerning capital increases and debt securities.

In addition, given the liquidity conditions observed during the past year on the Nasdaq in the biotechnology sector, the Board of Directors is proposing to the General Meeting a new resolution (27th resolution) in order to

extend the use of the At-the-Market equity financing program ("ATM Program") and thus provide additional flexibility. This delegation and its use within the framework of the ATM Program set up by the Company, as well as the envisaged discount, would enable the Company to broaden the number of investors likely to subscribe to the Company's shares, to implement a specific placement method and to have, once again, increased flexibility in the issue of shares and in the setting of the issue price of the securities.

The new delegations of authority mentioned in the 21st to 30th resolutions would cancel and replace the authorizations with the same purpose. The maximum nominal amount of the capital increases to take place immediately or in the future, that can be carried out by virtue of the delegations mentioned in the 21st to 29th resolutions cannot exceed the overall nominal ceiling of the capital increase of EUR 3,000,000 and a cumulative sub-ceiling of EUR 3,000,000 for the authorizations for issues with preferential subscription rights waived as specified in the 22nd to 29th resolutions, indicated in the table attached to this report.

In order to give the Company the needed flexibility in case of market transactions, the Board of Directors proposes to the General Assembly to give the Board of Directors the possibility to choose between two methods in order to fix the price for capital increases by public offering within the limit of 10% of the share capital per year (resolution n°24) and for capital increases through an issue reserved for certain categories of investor (resolution n°26 and n°27), the issue price will at least be equal, at the discretion of the Board:

- Either to the Company's closing share price on the regulated Euronext Paris stock market during the previous trading session prior to the setting of the price;
- Or to the volume weighted average prices of the Company's share on the regulated Euronext Paris stock market in the three

previous trading sessions prior to its being set;

In both cases, possibly discounted by a maximum of 20%.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the powers that are granted to it under this resolution.

If you approve these resolutions, the Board of Directors will establish, each time these authorizations are used, in compliance with applicable legislative and regulatory provisions, a report for the shareholders describing the final conditions of the transaction and indicating (i) the potential dilutive effect of the issue of marketable securities on the situation of each shareholder, (ii) the potential impact of the issue of marketable securities on the share of equity of the Company and (iii) the potential theoretical impact of the issue of the marketable securities on the market value of the share of the Company.

Authorization granted to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued immediately or in the future by the Company, with existing shareholders' preferential subscription rights maintained (21st resolution).

In the 21st resolution, the Board of Directors proposes to the General Shareholders' Meeting to grant it the authority to issue, on one or more occasions, in France and/or abroad, free of charge or for a price, maintaining the shareholders' preferential subscription right, of (i) common shares of the Company, and (ii) marketable securities convertible by any means, immediately or in the future, to common shares existing or to be issued, by the Company, the subscription for which may be settled either in cash or by offsetting receivables, limited to a ceiling in the nominal amount of EUR 3,000,000 with

the understanding that the ceiling is a common overall ceiling applicable to all financial delegations referred to in the 21st to 29th resolutions:

- the marketable securities convertible to the common shares to be issued by the Company immediately or in the future thus issued may include debt securities or warrants, or be related to the issue of such securities, or allow the issue thereof as intermediate securities;
- they may take the form of subordinated or unsubordinated securities, with a fixed or indefinite term, and be issued either in euros or in other currencies, or in any monetary units established by reference to several currencies;
- the nominal amount of debt securities thus issued by virtue of this delegation of authority cannot exceed EUR 150,000,000 and this common ceiling applies to all of financial delegations referred to in the 21st to 29th resolutions;
- the maturity of the borrowings (convertible to the common shares to be issued by the Company), other than those represented by perpetual securities, may not exceed 50 years. Borrowings (convertible to the common shares to be issued by the Company) may be interest bearing at a fixed- and/or floating rate, with or without capitalization of interest, be covered by guarantees or collateral, be redeemable, with or without premium, or be amortizable, on the basis that the securities may also be purchased on the stock market or included in a public offering or exchange bid by the Company;
- shareholders have a preemptive subscription right, on an irreducible basis, to a fixed number of common shares and marketable securities issued under this delegation, in proportion to their shareholding;

- the Board of Directors may institute for shareholders a right to subscribe, on a reducible basis, for an additional number of common shares or marketable securities to be issued, which will be exercised in proportion to their subscription rights and subject to the limit of their requests;
- if the irrevocable subscriptions and, if applicable, reducible subscriptions, do not result in the purchase of the entire issue, the Board of Directors may use all or some of the powers provided for, in the order it so determines, to: (i) limit the issue to the amount of subscriptions received, provided that it is at least three-quarters of the issue decided upon, (ii) freely allocate all or some of the unsubscribed securities to the investors of its choice, or (iii) offer all or some of the unsubscribed securities to the public on the French and/or international markets;
- issues of subscription warrants for shares of the Company can be made by subscription offering, but also by free allocation to the owners of old shares, and in the case of free allocation, of share subscription warrants;
- the Board of Directors would have the power to decide whether the allocation rights forming fractions would not be traded and that the corresponding shares would be sold.

Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued immediately or in the future by the Company, with shareholders' preferential subscription rights waived by public offering other than the public offerings referred to in section 1° of article L.411-2 of the French monetary and financial Code (22nd resolution)

In the 22nd resolution, the Board of Directors proposes to the General Shareholders' Meeting to grant it the authority to decide to

issue, with shareholders' preferential subscription rights waived, in a public offering, other than the public offerings referred to in the 1° of article L.411-2 of the Monetary and Financial Code once or several times, in the proportions and at the times it deems fit, both in France and abroad, of (i) common shares of the Company, and/or (ii) securities convertible, by any means, immediately or in the future to common shares existing or to be issued, by the Company, the subscription for which may be settled either in cash or by offsetting receivables.

Public offerings made under this resolution may be combined, as part of one or more simultaneous issues, with offerings within the provisions in section 1° of Article L.411-2 of the Monetary and Financial Code.

As part of this delegation of authority:

- the preferential subscription rights of the shareholders are waived;
 - the ceiling of the nominal amount of capital increase, immediately or in the future, resulting from all the issues carried out by virtue of this delegation of authority is set at EUR 3,000,000 and on condition that the nominal overall ceiling of EUR 3,000,000 specified in the 21st resolution is not reached;
 - the nominal amount of the debt securities thus issued by virtue of this delegation of authority cannot exceed EUR 150,000,000 and this common ceiling applies to all financial delegations referred to in the 21st to 29th resolutions;
 - The marketable securities convertible to the common shares to be issued by the Company immediately or in the future thus issued may include debt securities or warrants, or be related to the issue of such securities, or allow the issue thereof as intermediate securities;
- the Board of Directors may establish a priority right, which is irreducible and, where applicable, reducible for all or part of the issue, for shareholders to subscribe for common shares or marketable securities for which the Board sets the terms of exercise in the conditions set forth by Law, without giving rise to the creation of transferable rights;
 - if the subscriptions, including any made by shareholders, do not result in the purchase of the entire issue, the Board of Directors may limit the issue to the amount of subscriptions received, provided that it is at least three-quarters of the decided issue, and/or freely allocate all or some of the unsubscribed shares to the investors of its choice;
 - the issue price for common shares is at least equal to the minimum provided for by the laws and regulations prevailing at the time this delegation is used (currently the weighted average share price over the previous three trading days on the regulated Euronext stock market prior to the date preceding the beginning of the public offering, less a maximum discount of 10%);
 - the issue price of the marketable securities is such that the sum immediately received by the Company, increased, as necessary, by the sum that may be subsequently collected by the Company, is at least equal to the issue price referred to above, for each ordinary share issued because of the issue of these marketable securities.

Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued by the Company immediately or in the future, with preferential subscription rights waived, by public offering referred to in section 1° of Article L.411-2 of the Monetary and Financial Code (23rd resolution)

In the 23rd resolution, the Board of Directors

Proposes to the General Shareholders Meeting to grant it the authority to decide on the issue, through a public offering in the meaning of the 1° of Article L.411-2 of the Monetary and Financial Code (i) of common shares of the Company, and/or (ii) marketable securities convertible, by any means, to the common shares to be issued immediately or in the future by the Company, with shareholders' preemptive subscription rights waived.

As part of this delegation of authority:

- the preferential subscription rights of the shareholders are waived;
- in any event, in accordance with the Law, the nominal amount of the capital increases carried out by virtue of this resolution may not exceed 20% of the share capital per year at the time of the issue;
- the ceiling of the nominal amount of capital increase carried out, immediately or in the future, resulting from all issues carried out pursuant to this delegation of authority would be set at EUR 3,000,000 and this ceiling is common to the one mentioned in the 22nd resolution and provided that the overall nominal ceiling of EUR 3,000,000 specified in the 21st resolution is not reached;
- the nominal amount of the debt securities thus issued by virtue of this delegation of authority cannot exceed EUR 150,000,000 and this common ceiling applies to all financial delegations referred to in the 21st to 29th resolutions;
- The securities convertible to the common shares to be issued by the Company immediately or in the future thus issued may include debt securities or warrants, or be related to the issue of such securities, or allow the issue thereof as intermediate securities;
- if the subscriptions do not absorb the entire issue of shares and/or marketable securities giving entitlement to the Company's share capital under this resolution, the Board of Directors may limit the issue to the amount of subscriptions received, if it is at least three-quarters of the decided issue, and/or to freely allocate all or some of the unsubscribed shares to the investors of its choice;
- the issue price for common shares is at least equal to the minimum provided for by the laws and regulations prevailing at the time this delegation is used (currently the weighted average share price over the previous three trading days on the regulated Euronext stock market prior to the beginning of the public offering less a maximum discount of 10%);
- the issue price of the marketable securities is such that the sum immediately received by the Company, increased, as necessary, by the sum that may be subsequently collected by the Company, is at least equal to the issue price referred to above, for each ordinary share issued because of the issue of these marketable securities.

Authorization to the Board of Directors, in the case of an issue, with existing shareholders' preferential subscription rights waived by public offering, of common shares of the Company and/or securities convertible to common shares to be issued by the Company, to set the issue price in accordance with the terms and conditions set by the General meeting, of up to 10% of the share capital per year (24th resolution)

This authorization is granted to the Board of Directors, in compliance with the provisions of Articles L.225-136 and L.22-10-52 of the French Commercial Code, for a term of 26 months starting from the day of this Extraordinary General Shareholders' Meeting, for each of the issues decided upon in accordance with resolutions 22nd and 23rd, limited to 10% of the Company's capital (in

existence on the date that this delegation is used) per 12-month period at the time of issue, to waive the price-setting terms and conditions defined in resolutions 22nd and 23rd mentioned above, and to set the issue price of common shares and/or marketable securities issued according to the following terms and conditions:

a) the issue price of the common shares will be determined by the Board of Directors and will be at least equal, at the discretion of the Board:

- either to the Company's closing share price on the regulated Euronext Paris stock market during the previous trading session prior to the setting of the price,
- or to the volume weighted average prices of the Company's share on the regulated Euronext Paris stock market in the three previous trading sessions prior to its being set,

and possibly discounted by a maximum of 20%;

b) the issue price of marketable securities convertible to common shares to be issued shall be the amount received immediately by the Company, plus any amount likely to be received later by the Company, where applicable, i.e., for each ordinary share issued as a result of these marketable securities being issued, at least equal to the amount mentioned in paragraph "a)" above.

The total nominal amount of the Company's capital increase and the total amount of debt securities resulting from the issues carried out under this delegation shall be deducted from the capital increase ceiling and from the debt securities ceiling set forth in accordance with the resolution relating to the issue approved.

We specify that a possibility of a discount as high as 20% aims to facilitate the transaction depending on market conditions.

Authorization for the Board of Directors, in the case of a capital increase with existing shareholders' preferential subscription rights maintained or waived, to increase the number of shares to be issued (25th resolution)

This authorization gives the Board of Directors the authority to carry out additional capital increases in conditions identical to those of the initial issue. This allows the exercise of overallocation options, options that allow to increase the size of issues in the case of excess demands.

This authorization would be given to the Board of Directors, for a period of 26 months from the date of this General Meeting (except for the 26th and 27th resolutions for which this delegation would be valid for a period of 18 months), to decide within thirty days of the closing of the subscription period for the initial issue, for each of the issues with or without maintenance of preferential subscription rights decided pursuant to the 21st, 22nd and 23rd resolutions presented above and the 26th and 27th resolutions presented below, to increase the number of securities to be issued, within the time limits and within the limits provided for by the law and regulations applicable on the date of issue, by up to 15% of the initial issue and at the same price as that used for the initial issue, subject to the ceiling provided for in the resolution pursuant to which the issue is decided.

Delegation of authority to the Board of Directors, with shareholders' preferential subscription rights waived, to increase the Company's share capital through an issue reserved for certain categories of investors (26th resolution)

In the 26th resolution, the Board of Directors proposes to the General Shareholders' Meetings to delegate it the authority to decide on the capital increase on one or more occasions, at the time or times that it would determine and in the proportion that it would decide, to specific categories of investors.

We propose to the General Shareholders' Meeting to cover the following categories, identical to those proposed to the General Shareholders Meeting of June 25, 2021:

- i. physical and legal persons, including companies, trusts or investment funds, organized under French or foreign law, that habitually invest in the pharmaceutical, biotechnological, or medical technology sector; and/or
 - ii. companies, institutions, or entities of any type, French or foreign, that exercise a significant part of their business in the pharmaceutical, cosmetic, chemical, or medical devices and/or technologies or research in these sectors; and/or
 - iii. French or foreign investment services companies, or any foreign firm with an equivalent status, that could guarantee to carry out an issue to be placed with the persons described in (i) and/or (ii) above, and, in this context, to subscribe to securities that are issued.
- the ceiling of the nominal amount of capital increase carried out, immediately or in the future, resulting from all issues carried out pursuant to this delegation of authority would be set at EUR 3,000,000 and this ceiling is common to the one mentioned in the 22nd resolution and provided that the overall nominal ceiling of EUR 3,000,000 specified in the 21st resolution is not reached;
 - if the subscriptions do not absorb the entire issue of shares and/or marketable securities giving entitlement to the Company's share capital under this resolution, the Board of Directors may limit the issue to the amount of subscriptions received, provided that the amount is at least three-quarters of the decided issue, and/or to freely allocate all or part of the unsubscribed shares to the individuals of its choice;
 - the marketable securities convertible to the common shares to be issued by the Company immediately or in the future

thus issued may include debt securities or warrants, or be related to the issue of such securities, or allow the issue thereof as intermediate securities;

- the nominal amount of debt securities thus issued by virtue of this delegation of authority cannot exceed EUR 150,000,000 and this common ceiling applies to all financial delegations referred to in the 21st to 29th resolutions;

The Board of Directors will have full authority to implement this resolution, and in particular determine the list of beneficiaries from within the aforementioned category of investors who will benefit from the waiver of preferential subscription rights, including the features, amount and terms and conditions of any issue as well as the type of securities to be issued. In particular, it can determine the number to issue for each beneficiary and set, taking into consideration the indications contained in its report, the price of subscription of the said securities, their entitlement date as well as, if applicable, the duration, or the ways in which the marketable securities issued on the basis of this resolution are convertible to common shares to be issued by the Company, further specified that the amount received, or that will be receivable, by the Company for each of the shares issued as part of this delegation are determined by the Board of Directors and are to be at least equal:

- a) for ordinary shares issued under this authorization, at the choice of the Board of Directors:
 - either to the closing price of the share of the Company on the regulated Euronext Paris stock exchange at the time of the last trading session preceding its being set
 - or equal to the volume weighted average of prices of the share of the Company on the regulated Euronext Paris exchange in the three previous trading sessions prior to the setting of the issue price,
- possibly reduced by a maximum discount of 20%.

b) For marketable securities issued under this authorization other than shares, equal to the amount received immediately by the Company, plus any amount likely to be received later by the Company, where applicable, i.e., for each ordinary share issued as a result of these marketable securities being issued, at least equal to the amount mentioned in paragraph "a)" above.

We specify that a possibility of a discount as high as 20% aims to facilitate the transaction depending on market conditions.

This resolution may also be used in connection with the ATM Program set up by the Company on the U.S. market and registered with the Securities Commission Exchange (the "SEC") by the Company in September 2020 for the issuance of ordinary shares in the form of ADSs reserved for specialized investors falling within the above-mentioned categories, in particular following inquiries by such investors to the Company or to the bank in charge of the ATM Program (the "Sales Agent") ("reverse inquiries"), which was used for the first time in February 2021.

Shareholders are reminded that they may consult the Company's website to obtain information on the ATM Program and its use.

The delegation thus conferred to the Board of Directors is valid for an 18-month period starting from the date of this General Shareholders' Meeting.

Delegation of authority to the Board of directors, with shareholders' preferential subscription rights waived, to increase the Company's share capital through an issue reserved for certain categories of investors as part of an At-the-market equity financing program (27th resolution)

In the 27th resolution, the Board of Directors proposes that the Shareholders' Meeting delegate to it the authority to decide to increase the share capital, on one or more occasions, at the time or times it determines,

and, in the proportions, it determines, by issuing ordinary shares in the form of American Depositary Shares or American Depositary Receipts.

We propose to the Shareholders' Meeting to reserve the right to subscribe for them to any credit institution or any investment services provider, French or foreign, or any foreign institution with an equivalent status, intervening within the framework of an ATM program set up by the Company (or any equity financing program of the same nature which would replace it) and providing, within this framework, for the subscription of securities issued by the Company.

The purpose of this new authorization is to allow the extension of the ATM Program to the placement by the Sales Agent of new shares in the form of ADSs sold directly on the U.S. market, in accordance with the terms and conditions of trading of orders applicable to the market in concerned (dribble out method).

Such sales would be made at market price, in as many transactions as necessary, during one or more trading days, at the request of the Company, within the limit of the total amount, the duration and the minimum price indicated by the Company to the Sales Agent and within the limits provided for in this resolution.

The use of this resolution, which is subject to obtaining the necessary regulatory approvals, would enable the Company to issue to the Sales Agent the number of shares sold by the Sales Agent during the period in question (e.g. one trading day), at a subscription price corresponding to their weighted average price on the market. The Company retains full control over the activation or deactivation of the ATM Program, including during its execution.

The ceiling on the nominal amount of the capital increase resulting from all the issues carried out by virtue of the present delegation would be set at EUR 1,500,000 (which represents 15,000,000 shares representing

48.4% of the share capital as of 30 April 2022), subject to the overall nominal ceiling of 3,000,000 euros provided for in the 21st resolution not being reached.

In addition, the issues carried out under the ATM Program, in the form of "reverse enquiries" (under resolution 25) as well as "dribble outs" (under this resolution) are not subject to a Prospectus and therefore remain limited by the legal constraint of 20% of the share capital per 12-month period (cumulatively with the other eligible issues that would be carried out by the Company, if any) assessed at the date of implementation of the delegation by the Board of Directors in accordance with point 5 of Article 1 of Regulation (EU) 2017/1129 of June 14, 2017.

If subscriptions do not absorb the entire issue of shares issued under this resolution, the Board of Directors may limit the issue to the amount of subscriptions received, provided that this amount reaches at least three quarters of the issue decided upon, and/or freely allocate all or part of the unsubscribed securities among the persons of its choice.

The Board of Directors shall have full powers to implement the resolution and, in particular, to determine the list of beneficiary(ies) within the aforementioned category(ies) of beneficiaries in whose favor the preferential subscription right has been waived, and may determine the number of securities to be issued in favor of each beneficiary and to set, in the light of the indications contained in its report, the subscription price of the said securities, it being stipulated that the issue price of the ordinary shares and/or of the securities issued must be at least equal to :

- or the closing price of the Company's shares on the regulated market Euronext Paris during the last trading session prior to its determination,
- or the volume-weighted average (in the central order book and excluding off-market blocks) of the Company's share price on the regulated market Euronext Paris during the

last three trading sessions preceding the setting of the issue price;

possibly reduced by a maximum discount of 20%.

The delegation thereby granted to the Board of Directors would be valid for a period of 18 months from the date of this Meeting.

Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued by the Company in the event of a public exchange offer initiated by the Company, with shareholders' preemptive subscription rights waived (28th resolution).

We propose that you grant to the Board of Directors a delegation of authority to decide based on and in the conditions proposed in the 22nd resolution, on the issue of common shares of the Company or of marketable securities convertible to shares, immediately or in the future, by the Company, as compensation for the securities contributed in a public offering as part of an exchange component initiated in France or abroad, according to local rules, by the Company on the securities of a company whose shares are admitted for trading on a regulated market in the meaning of Article L. 22-10-54 of the French Commercial Code.

As part of this delegation of authority:

- the preferential subscription rights of the shareholders are waived;
- the ceiling of the nominal amount of capital increase carried out, immediately or in the future, resulting from all of the issues carried out by virtue of this delegation of authority is set at EUR 3,000,000 and this ceiling is common to the one set in the 22nd resolution and provided that the overall nominal ceiling of EUR 3,000,000 specified in the 21st resolution is not reached;

- the nominal amount of the debt securities thus issued cannot exceed EUR 150,000,000 and this common ceiling applies to all financial delegations referred to in the 21st to 29th resolutions.

Authorization for the Board of Directors to issue with existing shareholders' preferential subscription rights waived, common shares and/or securities convertible to common shares to be issued, to be used as payment for in-kind contributions to the Company consisting of equity securities or other securities convertible to shares (29th resolution)

We propose that you grant to the Board of Directors the delegation of authority to proceed, on the report of the Statutory Auditors, with the contributions to the issue of common shares of the Company and/or of marketable securities convertible to common shares to be issued immediately or in the future by the Company, in consideration of the in-kind contributions made to the Company and composed of capital securities and/or marketable securities convertible to the capital when the provisions of Article L.22-10-54 of the French Commercial Code are not applicable.

This delegation of authority would allow the Board of Directors to finance most efficiently, by issuing securities, acquisitions of securities of companies, whose shares are either not listed, or whose shares are listed (i) if they are not listed on a regulated market or (ii) if the transaction is not carried out as part of the public exchange offering. As part of this delegation of authority:

- The preferential subscription rights of shareholders may be, as needed, waived for the holders of shares or marketable securities, that are the object of in-kind contributions;
- the ceiling of the nominal amount of capital increase carried out, immediately or in the future, resulting from all of the issues carried out by virtue of this

delegation of authority is set at 10% of the capital of the Company (as existing at the date of this General Shareholders' Meeting) and this ceiling is applied against that of the EUR 3,000,000 set in the 22nd resolution and provided that the nominal overall ceiling of EUR 3,000,000 specified in the 21st resolution is not reached;

- the nominal amount of the debt securities thus issued cannot exceed EUR 150,000,000 and this common ceiling applies to all financial delegations referred to in the 21st to 29th resolutions.

Authorization to the Board of Directors to increase the Company's capital by incorporating reserves, profits, or premiums (30th resolution)

We propose that you delegate to the Board of Directors the authority to decide to increase the share capital on one or more occasions, at the time(s) and according to the terms and conditions that it determines, by successively or simultaneously incorporating reserves, profits, or premiums in the share capital, or any other amounts whose capitalization would be permitted by Law and under the Company's articles of incorporation, followed by the creation and allocation of bonus shares or by raising the nominal value of existing common shares, or by using a combination of these two methods.

The Board of Directors has the option to decide whether fractional rights will neither be traded nor sold and that the corresponding securities will be sold. The amounts arising from the sale shall be allocated to the rights holders within the time frame set forth by regulations.

The ceiling of the maximum nominal amount of the capital increase, immediate or future, resulting from all of the issues carried out under this delegation is set at EUR 1,300,000 provided that this ceiling is set autonomously and separately from the capital increase ceilings resulting from issues of common

shares and/or marketable securities authorized under other resolutions submitted to this General Shareholders' Meeting.

Employee and manager shareholders (30th to 34th resolutions)

These delegations of authority, detailed hereinafter, are intended to delegate to the Board of Directors the authority to issue and to retain the proceeds of issuing bonus shares (32nd resolution), share subscription or purchase options (33rd resolution) or detachable share subscription warrants (34th resolution) in order to recruit and to retain the talent that is essential to the growth of the Erytech Pharma Group. These delegations are granted for a duration of 38 months starting from the General Shareholders' Meeting (except for the delegation that is granted by the 34th resolution, which is for a duration of 18 months).

The General Shareholders' Meeting of June 25, 2021, adopted delegations with characteristics and durations similar to those which will be submitted to you at this General Shareholders' Meeting. The overall ceiling of these delegations has been set at 900,000 shares.

The Company's listing on Nasdaq, wished to align itself with the market standards and practices of this life sciences companies of this Exchange, particularly in terms of its policy on the allocation of equity incentive instruments. The equity compensation is indeed commonly used in the life science industry to compensate employees and attract key talent.

A study conducted by an external consultant indicated that the number of the Company's equity incentives instruments in circulation was less than that in common practice among companies listed on the Nasdaq. This study has further shown that, on an annual basis, US and European companies are granting around 5% of dilutive equity instruments and around 2% of shares and maintain a total overhang of approximately 17% and 6%, respectively.

We believe that equity compensation has been, and will continue to be, a critical component of our compensation package because it (i) contributes to a culture of ownership among our employees, directors, and officers, (ii) aligns our employees' interests with the interests of our other stockholders and (iii) preserves our cash resources. We therefore propose to increase the overall combined ceiling for any issues that may be made under the 32nd to 34th resolutions to 1,500,000 shares, which would represent approximately 5% of the Company's share capital.

In addition, the new delegations referred to in the 32nd to 34th resolutions may not exceed the sub-ceilings specific to each instrument, i.e. 800,000 shares for bonus shares, 1,200,000 shares for share subscription and/or share purchase options and 200,000 shares for detachable share subscription warrants, as indicated in the table attached to this report.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of this latter, to one or more Deputy Chief Operating Officers, the power that is granted to it under this resolution.

Delegation of authority to the Board of Directors to carry out capital increases reserved for employees enrolled in an Erytech Pharma Group savings plan, with shareholders' preferential subscription rights waived (31st resolution)

Article L. 225-129-6 para. 1 of the French Commercial Code specifies that for any delegation of authority to carry out a capital increase pursuant to Article L. 225-129-2 of the French Commercial Code, the Extraordinary General Shareholders' Meeting must approve a draft resolution for a capital increase to be made in the conditions specified in Articles L. 3332-18 et seq. of the French Labor Code.

With respect to the agenda of the Combined General Shareholders' Meeting, it is thus your duty to decide on such a proposal and to

resolve to delegate full authority to the Board of Directors to carry out the said capital increase reserved for employees enrolled in a company savings plan pursuant to the terms and conditions specified in Articles L. 3332-18 et seq. of the French Labor Code.

For this authorization to comply with the provisions of Article L. 225-129-6 of the French Commercial Code with respect to the delegations proposed in the 21st to 29th and 32nd to 33rd resolutions, it is necessary to:

- resolve to waive the shareholders' preferential subscription rights for new shares to be issued to employees of the Company and its affiliates who are enrolled in a company savings plan;
- resolve that the issue price for new shares shall be set by the Board of Directors by referencing the Company's share prices on the Euronext Paris stock market, with the understanding that this price cannot be greater than the average price over the past twenty (20) trading sessions preceding the day of the Board of Directors' decision to set the opening date for the subscription period, nor be more than 30% lower than this average price, or 40% when the lock-up period defined by the company savings plan is greater than or equal to 10 years;
- limit the maximum nominal amount of the capital increase that can be carried out by the Board of Directors, which may not increase the amount of said employees' equity investment (including the equity investment already held) to more than 3% of the total amount of share capital on the day that the Board of Directors decides to implement this authorization;
- resolve that the new shares will be subject to all provisions of the articles of association, and will be considered the same as old shares and will bear rights as of the first day of the year in which the capital increase took place;

- delegate full authority to the Board of Directors to decide upon and carry out this capital increase once pursuant to the terms set forth above, define the terms and conditions that the beneficiaries must meet, under the agreement that these terms and conditions can include employee seniority conditions, provided that the time period does not exceed six months, set the terms and conditions under which the shares will be issued and paid up, amend the by-laws, and generally take any additional steps that may be required;
- resolve that the capital increase authorized under this resolution will be carried out within one year starting from this General Shareholders' meeting.

This is the meaning of the resolution that we submit for your consideration, but that we propose to reject since, on the one hand, it is mandatory by law and, on the other hand, our Company has already put in place mechanisms for employee profit sharing.

Authorization for the Board of Directors to award bonus shares, existing or to be issued, with existing shareholders' preferential subscription rights waived, to corporate officers or employees of the Company or related companies (32nd resolution)

We propose that you authorize the Board of Directors, in compliance with Article L.225-197-1 *et seq.* and L. L.22-10-59 *et seq.* of the French Commercial Code and the provisions of the MiddleNext Code of Corporate Governance, for a duration of 38 months starting from the Extraordinary General Shareholders' Meeting, to carry out, on one or more occasions, for the employees of the Company or related companies or of certain categories of employees, as well as for the executive officers as defined by law, allocations of bonus shares or existing shares or shares to be issued by the Company, subject to the abstention periods required by law and in the conditions mentioned here below:

- the beneficiaries must be employees or corporate officers of the Company, or French or foreign companies or groups related to the Company or certain categories among them;
- this authorization shall entail the waiver, by the shareholders of existing common shares or common shares to be issued, of (i) their preferential subscription rights to future common shares that will be issued when the shares undergo final allocation, (ii) their entitlement to bonus common shares based on this authorization and (iii) any entitlement to the amount of reserves, profits or premiums on which the new shares will be based;
- the existing shares that may be allocated under this resolution must be acquired by the Company as part of a share buyback program authorized by the 19th resolution, submitted to this General Shareholders' Meeting pursuant to Article L.22-10-62 of the French Commercial Code, or any applicable previous or subsequent share buyback program;
- the total number of bonus common shares granted under this resolution may not exceed 800,000 shares, provided that the total nominal amount of capital increases that could result from this resolution cannot exceed the common ceiling of 1,500,000 shares for all issues carried out pursuant to the 32nd to 34th resolutions submitted to this General Shareholders' Meeting.

You are asked to authorize that the granting of these shares to their beneficiaries shall become final for all, or part of the shares allocated:

- at the end of a vesting period defined by the Board of Directors, which may not be less than one year;
- potentially at the end of a minimum period of retention by the beneficiaries starting from the final allocation of the

shares, the duration of which would be defined by the Board of Directors.

In accordance with law, the cumulative duration of the vesting periods and retention periods cannot be less than two years. In the event of the disability of a beneficiary meeting the conditions required by law, the final allocation of shares may take place before the end of the vesting period.

This authorization, which expires after 38 months, would put an end, for the unused fraction, to the authorization granted to the Board of Directors by the 23rd resolution of the General Shareholders' Meeting of June 25, 2021. The Board of Directors will inform the General Shareholders' Meeting of any allocations made under this resolution on a yearly basis, in accordance with Article L. 225-197-4 of the French Commercial Code.

Authorization for the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies in the Erytech Pharma Group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options (33rd resolution)

We propose that you authorize the Board of Directors, pursuant to Articles L. 225-177 et seq. and L.22-10-56 of the French Commercial Code, with respect to the provisions of the MiddleNext Code of Corporate Governance, for a duration of 38 months starting from the General Shareholders' Meeting, to grant, on one or more occasions, share subscription and purchase options on shares of the Company, in the following conditions:

- the beneficiaries must be employees or corporate officers of the Company, or French or foreign companies or groups related to the Company or certain categories among them;
- this authorization includes the shareholders' express waiver of their

preferential subscription rights to the shares that will be issued when these options are exercised;

- each option shall give entitlement to subscribe to or purchase a new or existing common share, as appropriate;
- the total number of bonus common shares granted under this resolution cannot exceed 1,200,000 shares, provided that the total nominal amount of capital increases that could result from this resolution cannot exceed the common ceiling of 1,500,000 total shares for all issues carried out pursuant to the 32nd to 34th resolutions submitted to this General Shareholders' Meeting;
- the shares that can be obtained by the exercise of the purchase options granted pursuant to this resolution proposed must be acquired by the Company;
- the share subscription or purchase price may not be less than 95% of the Company's average share price on the Euronext Paris regulated stock market in the twenty trading sessions prior to the day the options are granted. In addition, (ii) the exercise price of the share purchase options cannot be less than 95% of the average purchase price of shares held by the Company;
- the options allocated must be exercised within 10 years from the day they are granted by the Board of Directors. The Company's Extraordinary General Shareholders' Meeting is authorized to extend the aforementioned 10-year limitation at any time.

To implement this authorization, the Board of Directors can call on the help of a committee composed of members of its choice. This authorization, which expires after 38 months, would put an end, for the unused fraction, to the authorization granted to the Board of

Directors by the 24th resolution of the General Shareholders' Meeting of June 25, 2021.

The Board of Directors shall inform the General Shareholders' Meeting of the transactions carried out under this proposed resolution each year.

Authorization for the Board of Directors to issue share subscription warrants, with existing shareholders' preferential subscription rights waived, to corporate officers or employees of the Company or Erytech Pharma Group companies (34th resolution)

We propose that you authorize the Board of Directors to decide to increase the share capital, for a duration of 18 months, on one or more occasions and in the proportions and at the times that it determines, by issuing warrants, pursuant to the terms and conditions below and in accordance with Articles L. 225-129 to L. 225-129-6, L.22-10-49, L. 225-138 and L. 228-91 et seq. of the French Commercial Code:

- the beneficiaries must be employees, consultants or corporate officers of the Company, or French or foreign companies or groups related to it, or certain categories among them;
- this authorization will include, for those who hold share subscription warrants issued under this resolution, the express waiver of their preferential subscription rights attached to the warrants issued;
- one warrant gives the right to subscribe to one share of the Company;
- the total number of shares to which the warrants granted pursuant to this resolution would give the right to a number of shares greater than 200,000 shares, it being specified that the total nominal amount of capital increases that can result from this resolution cannot exceed the common ceiling of 1,500,000 shares for all issues that can be carried out pursuant to the 32nd to 34th resolutions;

- the subscription price must be at least equal to the volume-weighted average of the closing prices of the share recorded during a period of at least five consecutive trading days and at most thirty consecutive trading days among the thirty trading days preceding the setting of the subscription price, possibly reduced by a maximum discount of 5% at the time of allocation of the warrants;

To implement this authorization, the Board of Directors can call on the help of a committee composed of members of its choice.

This authorization, which expires after 18 months, would put an end, for the unused fraction, to the authorization granted to the Board of Directors by the 25th resolution of the General Shareholders' Meeting of June 25, 2021.

The Board of Directors shall inform the General Shareholders' Meeting of the transactions carried out under this resolution each year.

Powers to carry out formalities (35th resolution)

In the 35th resolution, your Board of Directors asks for all powers necessary to carry out all the required registration and publication formalities concerning this General Shareholders' Meeting.

The draft text of the resolutions submitted for your vote is attached hereto.

The Board of Directors

DRAFT RESOLUTIONS PROPOSED TO THE COMBINED GENERAL SHAREHOLDERS' MEETING OF JUNE 24, 2022

ORDINARY RESOLUTIONS

1. Approval of the financial statements for the year ended December 31, 2021

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary Shareholders' Meetings, and having reviewed the Board of Directors' reports and the Statutory Auditors' report on the financial statements, approves these reports and the financial statements for the year 2021 as submitted, as well as the transactions reflected in these statements and summarized in these reports, which show a net loss of EUR 48,643,093.61.

Pursuant to Article 223 *quater* of the French Tax Code, the General Shareholders' Meeting approves the expenses and charges provided in Article 39-4 of the said Code amounting to EUR 29,329, and the amount of potential tax that would be incurred as a result of these expenses and charges, which would amount to EUR 7,772.

2. Approval of the consolidated financial statements for the year ended December 31, 2021

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary Shareholders' Meetings, and having reviewed the Board of Directors' Reports and the Statutory Auditors' Report on the consolidated financial statements, hereby approves the Company's consolidated financial statements for this financial year ended December 31, 2021 as presented to it, and the transactions reflected in these statements and summarized in these reports, and showing a net loss of EUR 53,796,953.

3. Allocation of results for the year

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary Shareholders' Meetings and on the recommendation of the Board of Directors, decides to allocate the net loss for the year ended December 31, 2021, in the total amount of EUR 48,643,093.61 to the "Share Premium" account which will amount after allocation to EUR 21,407,975.74.

In accordance with legal provisions, it is hereby noted that the Company has not paid any dividends in the previous three years.

4. Approval of the special report of the statutory auditors on regulated agreements and commitments

The General Shareholders' Meeting, voting under the quorum and majority conditions required for Ordinary Shareholders' Meetings, having consulted the report of the Board of Directors and the special report of the Statutory Auditors on the agreements and commitments referred to in Articles L. 225-38 et seq. of the French Commercial Code, approves this report and the agreements and commitments described therein.

5. Approval of the information mentioned in article L.22-10-9 I of the French Commercial Code concerning the executive corporate officers' compensation for the year ended December 31, 2021

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary Shareholders' Meetings, and having reviewed the Board of Directors' Report on corporate governance described in article L.225-37 of the French

Commercial Code approves, in compliance with article L.22-10-34 I of the French Commercial Code, the information mentioned in article L.22-10-9 I of the French Commercial Code as detailed in section 3.1.2.1.2 of the 2021 Universal Registration Document.

6. Approval of the elements of total compensation and benefits of all kinds paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer

The General Shareholders' Meeting, voting under the quorum and majority required for Ordinary Shareholders' Meetings, and having reviewed the Board of Directors' Report on corporate governance described in article L.225-37 of the French Commercial Code approves, in compliance with article L.22-10-34 II of the French Commercial Code, the fixed, variable and exceptional elements of total compensation and the benefits of any type paid during financial year ended on December 31, 2021 or allocated under the same year to Gil BEYEN, Chief Executive Officer as detailed in section 3.1.2.1.1 of the 2021 Universal Registration Document.

7. Approval of the elements of total compensation and benefits of all kinds paid or allocated for the year ended December 31, 2021, to Jean-Paul KRESS, Chairman of the Board

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary Shareholders' Meetings, and having reviewed the Board of Directors' Report on corporate governance described in article L.225-37 of the French Commercial Code approves, in compliance with article L.22-10-34 II of the French Commercial Code, the fixed, variable and exceptional elements of total compensation and the benefits of any type paid during financial year ended on December 31, 2021 or allocated under the same year to Mr. Jean-Paul KRESS, Chairman of the Board as detailed in section 3.1.2.1.1 of the 2021 Universal Registration Document.

8. Approval of the compensation policy for executive corporate officers

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary General Shareholders' Meetings, and having reviewed the Board of Directors' report on corporate governance mentioned in article L. 225-37 of the French Commercial Code, approves, in compliance with article L.22-10-8 II of the French Commercial Code, the compensation policy applicable to executive corporate officers as detailed in section 3.1.2.2.2 of the 2021 Universal Registration Document.

9. Approval of the compensation policy for Board Members

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary General Shareholders' Meetings, and having reviewed the Board of Directors' report on corporate governance mentioned in article L. 225-37 of the French Commercial Code, approves, in compliance with article L.22-10-8 II of the French Commercial Code, the compensation policy applicable to Board members as detailed in section 3.1.2.2.3 of the 2021 Universal Registration Document.

10. Renewal of the term of office of Jean-Paul KRESS as Director

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary General Shareholders' Meetings, resolves, after reviewing the Board of Directors' report, to renew the term of office of Jean-Paul KRESS, residing 50 Gray Street Boston MA 02116 (United States) as Director for a three-year term, that will end at the close of the Ordinary Shareholders' Meeting to be held in 2025 to approve on the financial statements for the year ending December 31, 2024.

11. Renewal of the term of office of Gil BEYEN as Director

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary General Shareholders' Meetings, resolves, after reviewing the Board of Directors' report, to renew the term of office of Gil BEYEN, residing 96 South ST #4, Boston, MA 02111 (United States) as Director for a three-year term, that will end at the close of the Ordinary Shareholders' Meeting to be held in 2025 to approve on the financial statements for the year ending December 31, 2024.

12. Renewal of the term of office of Philippe ARCHINARD as Director

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary General Shareholders' Meetings, resolves, after reviewing the Board of Directors' report, to renew the term of office of Philippe ARCHINARD, residing 47 rue Professeur Deperet, 69160 Tassin-la-Demi-Lune (France), as Director for a three-year term, that will end at the close of the Ordinary Shareholders' Meeting to be held in 2025 to approve on the financial statements for the year ending December 31, 2024.

13. Renewal of the term of office of Luc DOCHEZ as Director

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary General Shareholders' Meetings, resolves, after reviewing the Board of Directors' report, to renew the term of office of Luc DOCHEZ, residing 8 Klein Vilvoordestraat 3078 Meerbeek (Belgium) as Director for a three-year term, that will end at the close of the Ordinary Shareholders' Meeting to be held in 2025 to approve on the financial statements for the year ending December 31, 2024.

14. Ratification of the appointment by cooptation of Sven ANDRÉASSON as Director

The General Shareholders' Meeting, ruling under the conditions of quorum and majority required for Ordinary General Shareholders' Meetings, decides, after reviewing the Board of Directors' report, to ratify the appointment of Sven ANDRÉASSON, residing at 3528 Reservoir Road NW, Washington D.C 20007 (United States), decided by the Board of Directors on January 4, 2022, as a Director, to replace the company Galenos SPRL, for the duration of the latter's term of office, i.e., until the end of the present Shareholders' Meeting.

15. Renewal of the term of office of Sven ANDRÉASSON as Director

The General Shareholders' Meeting, voting under the quorum and majority conditions required for Ordinary General Shareholders' Meetings, resolves, after reviewing the Board of Directors' report, to renew the term of office of Sven ANDRÉASSON, residing at 3528 Reservoir Road NW, Washington D.C 20007 (United States), as Director for a period of three years, which will expire at the end of the ordinary general meeting of shareholders to be held in 2025 to approve the financial statements for the financial year ending December 31, 2024.

16. Renewal of the term of office of KPMG S.A as co-statutory auditor

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary General Shareholders' Meetings, resolves, after reviewing the Board of Directors' report, to renew the terms of office of KPMG S.A, with its registered office located 2 Avenue Gambetta Tour Eqho, Paris la Défense 92066 Nanterre Cedex, registered under number 775 726 417 RCS Nanterre, as joint statutory auditor of the Company, for a six year term that will end at the close of the Ordinary General Meeting of Shareholders to be held in 2028 to approve the financial

statements for the year ending December 31, 2027.

17. Non-renewal of the term of office of SALUSTRO REYDEL as alternate statutory auditor

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary General Shareholders' Meetings, after reviewing the Board of Directors' report, having noted the term of office' expiration of SALUSTRO REYDEL with its registered office located Tour Eqho 2 Avenue Gambetta Paris la Défense 92066 Nanterre Cedex, registered under number 652 044 371 RCS Nanterre, as alternate auditor of the Company resolves not to renew the term of office of SALUSTRO REYDEL and not to proceed to its replacement.

18. Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on July 27, 2021

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary Shareholders' Meetings, and having reviewed the Board of Directors' report, as well as Section 422 of the U.S. Internal Revenue Code relating to the allocation of incentive stock options to persons who are U.S. Residents for tax purposes stipulated under the share subscription and/or purchase options plan adopted by the Board of Directors on July 27, 2021 (the "2021 Options Plan"), approves the 2021 Options Plan.

19. Authorization for the Company to buy back its own shares

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Ordinary Shareholders' Meetings, and having reviewed the Board of Directors' report, authorizes the Board of Directors, which may further delegate such authority, as provided for under Articles L.22-10-62 et seq. of the French Commercial Code, Articles 241-1 et seq. of the French Financial

Markets Authority (AMF) General Regulations and by the European regulation applicable to market abuse especially Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014 to purchase or to cause to be purchased securities of the Company under a share buyback program not to exceed 5% of share capital on the day of this General Shareholders' Meeting (it being specified that, where the shares are bought in order to favor liquidity under those conditions defined below, the number of shares taken into account for the calculation of the 5% limit corresponds to the number of bought shares, minus the number of shares resold during the period under this authorization).

The General Shareholders' Meeting decides that the Board of Directors may only purchase Company shares under the following conditions:

- **The maximum purchase price** shall not exceed ten (10) euros per share, or its equivalent in foreign currency, it being noted that this price will be adjusted as necessary to reflect capital transactions, in particular incorporation of reserves or free share allocations and/or share splits or reverse splits, and will be determined in accordance with the limits set by laws and regulations in place at the time this authorization is used (currently, the maximum purchase price per share, excluding costs, shall not be higher than that of the price of the last independent trade or, if it is higher, than the price of the highest current independent bid on the trading venues where the purchase is carried out);
- **Maximum volume:** the Company shall refrain from purchasing beyond the maximum daily volume of shares authorized by laws and regulations in place at the time this authorization is used (currently, 25% of the average daily number of shares traded on the regulated Euronext Paris stock market);

- This authorization, which supersedes and replaces the unused portion of the authorization granted by the General Shareholders' Meeting of June 25, 2021, under its eleventh resolution, is granted for a period of 18 months from the date of this General Shareholders' Meeting;
 - The purchases made by the Company under this authorization may under no circumstances cause the Company to hold, directly or indirectly, at any time, more than 10% of the shares making up the Company's share capital at the date of this General Shareholders' Meeting;
 - These shares may be purchased or transferred by any means, through regulated markets, a multilateral trading facility and/or any other financial market located outside the European Economic Area, with a systematic internalizer, in accordance with the Law and regulations in force on the date of the transactions in question and at such time as the Board of Directors or the person acting on the delegation of the Board shall decide, outside of black-out periods, it being noted that the Board of Directors cannot, unless authorized in advance by the General Shareholders' Meeting, make use of this authorization in a period of a takeover bid initiated by a third party targeting the shares of the Company, until the end of the takeover period. Orders may not be placed during a bidding period and orders placed at the beginning of such periods may not be modified during the period.
- way of the award of bonus shares or performance share in accordance with Articles L. 225-197-1 et seq. and L.22-10-59 et seq. of the French Commercial Code;
- increasing the market liquidity of the share by means of one or more investment services providers acting independently under a liquidity contract, pursuant to market practices recognized by the French Financial Markets Authority (AMF), provided that the number of shares used to calculate the aforementioned 10% limit corresponds to the number of shares purchased, less the number of shares resold during the term of this authorization;
 - reducing the Company's share capital in application of the 20th resolution of this General Meeting of Shareholders, if adopted;
 - allocating shares to cover debt securities that are convertible or that can be exchanged against Company shares or any other type of securities giving access to shares of the Company, by conversion, presentation of a warrant, reimbursement or exchange; and
 - more generally, carrying out any transaction that may be authorized by Law or any market practice that may be permitted by the market authorities, based on the understanding that in such event, the Company would inform its shareholders through a statement.

This authorization is granted primarily for the purposes of:

- awarding shares to employees or corporate officers of the Company and French or foreign companies or groups that may be legally connected with it, particularly in the context of employee participation in the Company's expansion via employee shareholding and company savings plans, stock options plan, or by

The Board of Directors shall inform the General Shareholders' Meeting of any transactions carried out by virtue of this authorization, in accordance with the Law.

Full authority is granted to the Board of Directors, which may further delegate such authority, to decide on and implement this authorization and in particular:

- specify, if necessary, its terms, approve its procedures and, where applicable, prepare

a description of the share buyback program pursuant to Article 241-2 of the French Financial Markets Authority (AMF) General Regulations and publish this in accordance with the procedures described in Article 221-3 of these Regulations, prior to completing the share buyback program;

- place any share trading order, and sign any purchase, sale or transfer deed;
- enter into any agreement, make any statement, carry out any formalities and, more generally, take all necessary and appropriate measures.

EXTRAORDINARY RESOLUTIONS

20. Authorization for the Board of Directors to reduce the Company's share capital by canceling the treasury shares held by the Company

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary Shareholders' Meetings, having reviewed the Board of Directors' Report and the Statutory Auditors' special report, provided that the 19th resolution above is adopted, and ruling in accordance with Articles L.22-10-62 *et seq.* of the French Commercial Code:

- terminates, with immediate effect, the unused portion of the similar delegation granted by the twelfth resolution of the General Shareholders' Meeting of June 25, 2021;
- authorizes the Board of Directors to cancel, in the proportions and at the times it deems fit, once or several times, all or some of the Company's common shares purchased under the share buyback program authorized by the 19th resolution submitted to this General Shareholders' Meeting or other share buyback programs authorized previously or subsequently, and to reduce the share capital by the total nominal amount of the shares thus canceled up to a maximum of 10% of the Company's share capital per 24-month period, on the understanding that the 10% limit applies to a number of shares adjusted, where applicable, on the basis of the transactions carried out subsequent to this General Shareholders' Meeting that may affect the share capital;

- decides that the Board of Directors cannot, unless previously approved by the General Shareholders Meeting, make use of this authorization starting from the deposit by a third-party of a public takeover bid targeting the securities of the Company and until the end of the takeover period;
- decides to allocate any positive difference between the purchase price and nominal value of the common shares to the "Issue Premiums" account or to any other available reserves item, including the legal reserve, within the limit of 10% of the capital reduction made.

The General Shareholders' Meeting grants full authority to the Board of Directors, which may further delegate such authority in accordance with the Law, to:

- reduce the capital resulting from the cancellation of common shares;
- approve the final amount of the capital reduction;
- set the procedures for the capital reduction and record its completion;
- deduct the difference between the book value of the canceled shares and their nominal value from "issue premiums" or any available reserves line item;
- amend the articles of incorporation accordingly and carry out any required formalities (particularly with the French Financial Markets Authority); and

- more generally, take all necessary and appropriate measures to implement this authorization.

The authorization thus granted to the Board of Directors is valid for a period of 18 months from the date of this General Shareholders' Meeting.

21. Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued immediately or in the future by the Company, with existing shareholders' preferential subscription rights maintained

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, having reviewed the Board of Directors' report and the Statutory Auditors' special report, and duly noting that the share capital has been paid up in full, and acting in accordance with Articles L. 225-129 et seq. of the French Commercial Code, especially Article L. 225-129-2, and Articles L. 228-91 et seq. of said Code:

- terminates, with immediate effect, the unused portion of the delegation granted by the thirteenth resolution of the General Shareholders' Meeting of June 25, 2021;
- delegates to the Board of Directors, for a period of 26 months from the date of this General Shareholders' Meeting, the authority to decide to issue, on one or more occasions, at the time or times it sees fit and in the proportions it deems appropriate, both in France and abroad, with shareholders' preemptive subscription rights maintained, (i) common Company shares, and (ii) marketable securities convertible by any means to the common shares to be issued immediately or in the future by the Company, the subscription for which may be settled either in cash or by offsetting receivables.

The cap for the nominal amount of the Company's immediate or future capital increase resulting from all issues carried out by virtue of this delegation is set at EUR 3,000,000 on the understanding that (i) this cap applies to all issues likely to be made by virtue of the 21st to 29th resolutions submitted to this General Shareholders' Meeting, and that, consequently, the nominal amount of the capital increases to be carried out by virtue of the aforementioned resolutions cannot exceed this cap, and (ii) this cap is set excluding the nominal amount of any common shares of the Company that may be issued as a result of legal and contractual adjustments made to protect holders of rights attached to securities convertible to common shares.

Marketable securities giving access to the common shares to be issued by the Company immediately or in the future thus issued may include debt securities or warrants, or be related to the issue of such securities, or allow the issue thereof as intermediate securities.

They may take the form of subordinated or unsubordinated securities with a fixed or indefinite term, and be issued either in euros, or in other currencies, or in any monetary units established by reference to several currencies.

The maximum nominal value of such debt securities may not exceed EUR 150,000,000 or the equivalent of that amount on the date of the decision to issue, it being understood that (i) such amount does not include redemption premiums above par, if any, and that (ii) it is an overall ceiling covering all debt securities that may be issued under the 21st to 29th resolutions submitted to this General Shareholders' Meeting, and that, consequently, the par value of the debt securities liable to be issued pursuant to the above resolutions may not be greater than that ceiling. This ceiling is independent from the debt securities whose issue would be decided on or authorized by the Board of Directors in accordance with Article L. 228-40 of the French Commercial Code.

The maturity of the borrowings (giving access to the common shares to be issued by the Company), other than those represented by perpetual securities, may not exceed 50 years. Borrowings (giving access to the common shares to be issued by the Company) may be interest bearing at a fixed and/or floating rate, with or without capitalization of interest, be covered by guarantees or collateral, be redeemable, with or without premium, or be amortizable, on the basis that the securities may also be purchased on the stock market or included in a public offering or exchange bid by the Company.

Shareholders have preemptive subscription rights to a fixed number of common shares and marketable securities issued under this resolution, in proportion to their shareholding.

The Board of Directors may institute for shareholders a right to subscribe an additional number of common shares or marketable securities to be issued, which will be exercised in proportion to their subscription rights and subject to the limit of their requests.

If the subscriptions for excess shares and, as per the case, for precise numbers of shares, do not absorb the entire issue of shares or marketable securities giving entitlement to the Company's share capital under this resolution, the Board of Directors may use the facilities of Article L. 225-134 of the French Commercial Code, in whatever order it determines, or only some of them, especially those for limiting the number of subscriptions, provided that this amount reaches at least three-quarters of the issue decided upon, or to offer a portion of unsubscribed shares to the public.

The General Shareholders' Meeting duly notes that in accordance with the provisions in paragraph 6 of Article L. 225-132 of the French Commercial Code, this delegation includes the shareholders' waiver of their preemptive rights to subscribe common

Company shares to which the marketable securities issued based on this delegation may entitle them.

The General Shareholders' Meeting decides that issues of Company share subscription warrants may be made through an invitation to subscribe as well as by a bonus allotment to the owners of existing shares and that, in the event of a bonus allotment of share subscription warrants, the Board of Directors shall have the option to decide that allotment rights forming odd lots shall not be transferable and that the corresponding securities shall be sold.

The Board of Directors will establish the features, amount and terms and conditions of any issue and of the securities issued. In particular, it will determine the category of the securities issued and will set their subscription price, their ex-dividend date, which may be retroactive, and the term or conditions for exercising the rights attached to the securities issued. The Board of Directors may, where applicable, amend the terms and conditions of the securities issued by virtue of this resolution during the life of the securities concerned and in accordance with applicable laws and regulations. The Board of Directors may also, where applicable, make all adjustments intended to consider the impact of transactions on the Company's capital and define, in compliance with the applicable laws and regulations and when appropriate the applicable contractual terms providing other adjustments cases, the conditions under which the rights of holders of marketable securities giving access to the capital shall be protected, where applicable.

The Board of Directors shall have full authority to implement this resolution, including entering into any agreement to this effect, in particular to ensure that any issue is completed successfully, and to carry out, in one or more offerings and in the amount and on the dates it deems appropriate, in France and/or abroad, as applicable, the aforementioned issues – as well as defer

them, where appropriate – and to record their completion and make the corresponding amendments to the articles of incorporation, carry out any formalities and disclosures, and call for any authorizations that may be necessary to carry out and complete these issues successfully.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the power that is granted to it under this resolution.

22. Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued immediately or in the future by the Company, with shareholders' preferential subscription rights waived by public offering other than the public offerings referred to in section 1° of article L.411-2 of the French monetary and financial Code

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary Shareholders' Meetings, having deliberated and reviewed the Board of Directors' Report and the Statutory Auditors' special report, and having confirmed that the share capital has been paid up in full, in accordance with Articles L. 225-129 et seq. of the French Commercial Code, particularly Article L. 225-129-2 and Articles L.225-135, L.225-136, L.22-10-51 and L.22-10-52, as well as Articles L. 228-91 et seq. of this Code:

- terminates, with immediate effect, the unused portion of the delegation granted by the fourteenth resolution of the General Shareholders' Meeting of June 25, 2021,
- delegates to the Board of Directors, for a period of 26 months from the date of this General Shareholders' Meeting, the authority to decide to issue through a public offer other than the public offerings mentioned in section 1° of article L.411-2 of

the Monetary and Financial code, on one or more occasions, at the time or times it sees fit and in the amounts it deems appropriate, both in France and abroad, (i) common Company shares, and (ii) marketable securities giving access by any means to the common shares to be issued immediately or in the future by the Company, the subscription for which may be settled either in cash or by offsetting receivables, with shareholders' preemptive subscription rights waived.

Public offerings made under this resolution may be combined, as part of one or more simultaneous issues, with public offerings within the provisions in section 1° of Article L. 411-2 of the French Monetary and Financial Code. The General Shareholders' Meeting decides to remove shareholders' preemptive rights to subscribe these common shares and marketable securities.

The cap for the nominal amount of the Company's immediate or future capital increase resulting from all issues carried out by virtue of this delegation is set at EUR 3,000,000 on the understanding that (i) the nominal amount of all capital increases likely to be made under this resolution as well as under the 21st to 29th resolutions submitted to this General Shareholders' Meeting cannot exceed the overall ceiling of EUR 3,000,000 set in the 21st resolution, and (ii) this cap is set excluding the nominal amount of any common Company shares that may be issued as a result of legal and contractual adjustments made to protect holders of rights attached to securities convertible to common shares.

Marketable securities giving access to the common shares to be issued by the Company immediately or in the future thus issued may include debt securities or warrants, or be related to the issue of such securities, or allow the issue thereof as intermediate securities. The provisions regarding similar securities that may be issued pursuant to the 21st resolution above will apply to their issue, during their existence, to their convertibility

to common shares to be issued by the Company, and to their redemption, seniority, or amortization.

The maximum nominal value of such debt securities may not exceed EUR 150,000,000 or the equivalent of that amount on the date of the decision to issue, it being understood that (i) such amount does not include redemption premiums above par, if any, and that (ii) it is an overall ceiling covering all debt securities that may be issued under the 21st to 29th resolutions submitted to this General Shareholders' Meeting, and that, consequently, the par value of the debt securities liable to be issued pursuant to the above resolutions may not be greater than that ceiling. This ceiling is independent from the debt securities whose issue would be decided on or authorized by the Board of Directors in accordance with Article L. 228-40 of the French Commercial Code.

The Board of Directors may establish a priority right, which would be irreducible and where applicable reducible for all or part of the issue, for shareholders to subscribe common shares or marketable securities for which the Board would set the exercise terms and conditions under the conditions set forth by Law, without giving rise to the creation of transferable rights.

If the subscriptions do not absorb the entire issue of shares and/or marketable securities giving entitlement to the Company's share capital under this resolution, the Board of Directors may use the facilities of Article L. 225-134 of the French Commercial Code, in whatever order it determines, or only some of them, especially those for limiting the number of subscriptions, provided that this amount reaches at least three-quarters of the issue decided upon.

The General Shareholders' Meeting duly notes that this delegation includes the shareholders' waiver of their preemptive rights to subscribe for common Company shares to which the marketable securities

issued based on this delegation may entitle them.

The Board of Directors will establish the features, amount and terms and conditions of any issue and of the securities issued. In particular, it will determine the category of the securities issued and will set their subscription price, their ex-dividend date, which may be retroactive, and the term or conditions for exercising the rights attached to the securities issued; it may, where applicable, amend the terms and conditions of the securities issued by virtue of this resolution during the term of the securities concerned and in accordance with applicable laws and regulations; it may also, where applicable, make all adjustments intended to take into account the impact of transactions on the Company's capital and define, in compliance with the applicable laws and regulations and when appropriate the applicable contractual terms providing others adjustments cases the conditions under which the rights of holders of marketable securities giving access to the capital shall be protected, as the case may be, provided that:

- a) the issue price for common shares is at least equal to the minimum provided for by the laws and regulations prevailing at the time of using this delegation (currently the weighted average of the share price over the last three trading days on the regulated Euronext stock market preceding the beginning of the public offering, less a maximum discount of 10%), after this amount is corrected, if necessary, to reflect the difference in settlement date;
- b) the issue price of the marketable securities is such that the sum immediately received by the Company, increased, if necessary, by the sum that may be subsequently collected by the Company, is at least equal to the issue price referred to in paragraph a) above, for each common share issued because of the issue of these marketable securities.

The Board of Directors shall have full authority to implement this resolution, including entering into any agreement to this effect, in particular to ensure that any issue is completed successfully, and to carry out, in one or more offerings and in the amount and on the dates it deems appropriate, in France and/or abroad, as applicable, the aforementioned issues – as well as defer them, where appropriate – and to record their completion and make the corresponding amendments to the articles of incorporation, carry out any formalities and disclosures, and call for any authorizations that may be necessary to carry out and complete these issues successfully.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the power that is granted to it under this resolution.

23. Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued by the Company immediately or in the future, with preferential subscription rights waived, by public offering referred to in section 1° of article L.411-2 of the French monetary and financial Code

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, having reviewed the Board of Directors' report and the Statutory Auditors' special report and duly noted that the share capital has been paid up in full, and acting in accordance with Articles L. 225-129 et seq. of the French Commercial Code, in particular Article L. 225-129-2, and with Articles L.225-135, L.225-136, L.22-10-51, L.22-10-52 and L. 228-91 et seq. of said Code and Article L. 411-2 1° of the French Monetary and Financial Code:

- terminates, with immediate effect, the unused portion of the delegation granted

by the fifteenth resolution of the General Shareholders' Meeting of June 25, 2021,

- delegates to the Board of Directors, for a period of 26 months from the date of this General Shareholders' Meeting, the authority to decide to issue through an offer in connection with public offerings mentioned in section 1° of Article L. 411-2 of the French Monetary and Financial Code, (i) common Company shares, and (ii) marketable securities giving access by any means to the common shares to be issued immediately or in the future by the Company, with shareholders' preemptive subscription rights waived.

The General Shareholders' Meeting decides to remove shareholders' preemptive rights to subscribe these shares and marketable securities to be issued by means of public offerings mentioned in section 1° of Article L. 411-2 of the Monetary and Financial Code under the conditions stipulated in this resolution.

The cap for the nominal amount of the Company's immediate or future capital increase resulting from all issues carried out by virtue of this delegation is set at EUR 3,000,000 on the understanding that (i) such cap is shared with the ceiling set forth in the 22nd resolution and deducted from it and (ii) the nominal amount of all capital increases likely to be made by virtue of this resolution as well as the 21st to 29th resolutions submitted to this General Shareholders' Meeting cannot exceed the overall ceiling of EUR 3,000,000 set in the 21st resolution, and (iii) this cap is set excluding the nominal amount of any common Company shares that may be issued as a result of legal and contractual adjustments made to protect holders of rights attached to securities convertible to common shares. It is hereby specified that, in any event, in accordance with the law, the nominal amount of the capital increases carried out by virtue of this resolution may not exceed 20% of the share capital per year at the time of the issue.

Marketable securities giving access to the common shares to be issued by the Company immediately or in the future thus issued may include debt securities or warrants, or be related to the issue of such securities, or allow the issue thereof as intermediate securities. The provisions regarding similar securities that may be issued pursuant to the 21st resolution will apply to their issue, during their existence, to their convertibility to common shares to be issued by the Company, and to their redemption, seniority, or amortization.

The maximum nominal value of such debt securities may not exceed EUR 150,000,000 or the equivalent of that amount on the date of the decision to issue, it being understood that (i) such amount does not include redemption premiums above par, if any, and (ii) it is an overall ceiling covering all debt securities that may be issued under the 21st to 29th resolutions submitted to this General Shareholders' Meeting, and that, consequently, the par value of the debt securities liable to be issued pursuant to the above resolutions may not be greater than that ceiling. This ceiling is independent from the debt securities whose issue would be decided on or authorized by the Board of Directors in accordance with Article L. 228-40 of the French Commercial Code.

If the subscriptions do not absorb the entire issue of shares and/or marketable securities giving entitlement to the Company's share capital under this resolution, the Board of Directors may limit the issue to the amount of subscriptions received, if it is at least three-quarters of the decided issue, and/or to freely allocate all or some of the unsubscribed shares to the individuals of its choice.

The General Shareholders' Meeting duly notes that this delegation includes the shareholders' waiver of their preemptive rights to subscribe for common Company shares to which the marketable securities issued on the basis of this delegation may entitle them.

The Board of Directors will establish the features, amount and terms and conditions of any issue and of the securities issued. In particular, it will determine the category of the securities issued and will set their subscription price, their ex-dividend date, which may be retroactive, and the term or conditions for exercising the rights attached to the securities issued; it may, where applicable, amend the terms and conditions of the securities issued by virtue of this resolution during the term of the securities concerned and in accordance with applicable laws and regulations; it may also, where applicable, make all adjustments intended to take into account the impact of transactions on the Company's capital and define, in compliance with the applicable laws and regulations and when appropriate the applicable contractual terms providing others adjustments cases, the conditions under which the rights of holders of marketable securities giving access to the capital shall be protected, as the case may be, provided that:

- a) the issue price for common shares is at least equal to the minimum provided for by the laws and regulations prevailing at the time of using this delegation (currently the weighted average of the share price over the last three trading days on the regulated Euronext stock market preceding the beginning of the public offering, less a maximum discount of 10%), after this amount is corrected, if necessary, to reflect the difference in settlement date;
- b) the issue price of the marketable securities is such that the sum immediately received by the Company, increased, if necessary, by the sum that may be subsequently collected by the Company, is at least equal to the issue price referred to in paragraph a) above, for each common share issued because of the issue of these marketable securities.

The Board of Directors shall have full authority to implement this resolution, including entering into any agreement to this

effect, in particular to ensure that any issue is completed successfully, and to carry out, in one or more offerings and in the amount and on the dates it deems appropriate, in France and/or abroad, as applicable, the aforementioned issues – as well as defer them, where appropriate – and to record their completion and make the corresponding amendments to the articles of incorporation, carry out any formalities and disclosures, and call for any authorizations that may be necessary to carry out and complete these issues successfully.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the power that is granted to it under this resolution.

24. Authorization to the Board of Directors, in the case of an issue, with existing shareholders' preferential subscription rights waived by public offering, of common shares of the Company and/or securities convertible to common shares to be issued by the Company, to set the issue price in accordance with the terms and conditions set by the General Meeting, of up to 10% of the share capital per year

The General Shareholders' Meeting, voting under the rules of quorum and majority required for extraordinary general shareholders' meetings, after having read the Board of Directors' Report and the Statutory Auditors' special report, and voting in accordance with Articles L.225-136 and L.22-10-52 of the French Commercial Code:

- authorizes the Board of Directors, for a 26-month period starting from the day of this General Shareholders' Meeting, for each of the issues decided upon in accordance with the 22nd and 23rd resolutions above, up to a limit of 10% of the Company's capital (in existence on the date that this delegation is implemented) per 12-month period at the time of issue, to override the

price-setting terms and conditions defined in the aforementioned 22nd and 23rd resolutions, and to set the issue price of common shares and/or securities issued according to the following terms and conditions:

- a) The issue price of the common shares will be determined by the Board of Directors and will be at least equal, at the discretion of the Board:
 - Either to the Company's share price on the regulated Euronext Paris stock market during the last trading session prior to the price being set;
 - or to the volume weighted average prices of the Company's share at closing on the regulated Euronext Paris stock market in the three previous trading sessions preceding its being set,

and possibly discounted by a maximum of 20%;

- b) The issue price of marketable securities convertible to common shares to be issued shall be the amount received immediately by the Company, plus any amount likely to be received later by the Company, where applicable, i.e., for each common share issued as a result of these marketable securities being issued, at least equal to the amount mentioned in paragraph "a)" above.

The total nominal amount of the Company's capital increase and the total amount of debt securities resulting from the issues carried out under this delegation shall be deducted from the capital increase ceiling and from the debt securities ceiling set forth in accordance with the resolution relating to the issue approved.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the power that is granted to it under this resolution.

25. Authorization for the Board of Directors, in the case of a capital increase with existing shareholders' preferential subscription rights maintained or waived, to increase the number of shares to be issued

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, after having read the Board of Directors' Report and the Statutory Auditors' special report, and voting in accordance with Article L. 225-135-1 of the French Commercial Code:

- terminates, with immediate effect, the unused portion of the delegation granted by the seventeenth resolution of the General Shareholders' Meeting of June 25, 2021,
- authorizes the Board of Directors to decide to increase the number of securities to be issued, subject to complying with the ceiling(s) set forth in accordance with the resolution relating to the issue approved, for a 26-month period starting from this General Shareholders' Meeting (except for the 26th and 27th resolutions, for which this delegation is valid for an 18-month period), and decided on within the time limits set forth by the laws and regulations in effect on the day of the issue (on the day of this General Shareholders' Meeting, within thirty days of the subscription's closure, within 15% of the initial issue and at the same price as the price used for the initial issue) for each of the issues, while either maintaining or waiving shareholder preferential subscription rights, decided on in accordance with the 21st, 22nd and 23rd resolutions above and the 26th and 27th resolutions below.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the power that is granted to it under this resolution.

26. Delegation of authority to the Board of Directors, with shareholders' preferential subscription rights waived, to increase the Company's share capital through an issue reserved for certain categories of investors

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, after having read the Board of Directors' Report and the Statutory Auditors' special report, in accordance with Articles L. 225-138 and L. 225-129-2 of the French Commercial Code:

- terminates, with immediate effect, the unused portion of the delegation granted by the eighteenth resolution of the General Shareholders' Meeting of June 25, 2021,
- delegates the authority to the Board of Directors, which may further delegate such authority as provided by law, to decide to increase the share capital a maximum nominal amount of EUR 3,000,000 one or more times, at the time(s) it sets forth and in the proportion it deems fit (provided that (i) a portion of the ceiling is shared with the ceiling set forth in the 22nd resolution and deducted from it, and that (ii) the total nominal amount of capital increases likely to result from this resolution, as well as the 21st to 29th resolutions submitted to this General Shareholders' Meeting, may not exceed the total ceiling of EUR 3,000,000 set forth in the 21st resolution by issuing shares as well as any other securities convertible to shares to be issued immediately or in the future by the Company.

The General Shareholders' Meeting decides that the marketable securities providing access to common shares to be issued by the Company either immediately or in the future that have already been issued may consist of debt securities or warrants or may be associated with the issue of such securities or allow the issue as intermediate securities. The maximum nominal value of such debt

securities may not exceed EUR 150,000,000 or the equivalent of that amount on the date of the decision to issue; (i) this amount does not include redemption premiums above par, if any, and that (ii) this amount is an overall ceiling covering all debt securities that may be issued under the 21st to 29th resolutions submitted to this General Shareholders' Meeting.

The General Shareholders' Meeting decides to remove shareholders' preemptive subscription rights to the securities covered by this resolution and to reserve the right to subscribe for them to:

- i. physical and legal persons, including companies, trusts or investment funds or other investment entities in any form, organized under French or foreign law, that habitually invest in the pharmaceutical, biotechnological, or medical technology sector; and/or
- ii. companies, institutions, or entities of any type, French or foreign, that exercise a significant part of their business in the pharmaceutical, cosmetic, chemical, or medical devices and/or technologies or research in these sectors; and/or
- iii. French or foreign investment services companies, or any foreign firm with an equivalent status, that could guarantee to carry out an issue to be placed with the persons described in (i) and/or (ii) above, and, in this context, to subscribe to securities that are issued.

If the subscriptions, including those made by shareholders, where applicable, do not result in the purchase of the entire issue, the Board of Directors may limit the issue to the amount of subscriptions, provided that it is at least three-quarters of the decided issue, and/or to freely allocate all or some of the unsubscribed shares to the individuals of its choice.

This delegation shall act as a waiver by shareholders of their preferential subscription rights to shares to which the issued marketable securities will entitle, for those

shareholders who hold marketable securities providing access to the Company's capital.

The General Meeting resolves that the Board of Directors will have full authority, and may further delegate such authority in accordance with the law, to implement this resolution, and in particular determine the list of beneficiaries from within the aforementioned category of investors who will benefit from the waiver of preferential subscription rights, to proceed with any adjustments in order to take into account the impact of operations on the Company's capital, and to settle, in compliance with the applicable laws and regulations and when appropriate the applicable contractual terms providing others adjustments cases and settle the features, amount and terms and conditions of any issue as well as the type of securities to be issued.

In particular, it shall determine the number of securities to be issued to each beneficiary and shall define the subscription price of said securities, their entitlement date which may be retroactive, as well as the duration, or the terms and conditions under which the marketable securities issued under this resolution will provide access to common shares to be issued by the Company and by which the rights of holders of securities giving access to the capital will be preserved where applicable, given the instructions contained in its report. Any amount owed to the Company should at least be equal to:

a) For common shares issued under this delegation of authority at the Board's discretion:

- Either at the closing price of the Company's share on the regulated Euronext Paris stock market at the last trading session preceding its being set;
- Or the volume-weighted average price (in the central order book and excluding off-market blocks) of the Company's share prices on the regulated Euronext Paris stock market from the three trading sessions preceding the date that the issue price was set. This average may be

adjusted for differences in the entitlement date, where applicable

and may potentially be discounted by a maximum of 20%;

b) marketable securities issued under this delegation will be such that the amount received immediately by the Company plus any amount likely to be received subsequently by the Company, where applicable, be at least equal to the amount listed in paragraph "a)" above, for each common share issued as a result of the issue of these marketable securities.

The General Meeting resolves that the amount of any additional capital increases necessary to protect the rights of holders of securities giving access to Company capital shall be added to the EUR 3,000,000 amount defined above.

In accordance with Article L. 225-138 of the French Commercial Code, the Board of Directors will prepare a report for the next Ordinary General Shareholders' Meeting describing the definitive terms and conditions of the transactions completed, in accordance with this resolution.

The authorization thus granted to the Board of Directors is valid for a period of 18 months from the date of this General Shareholders' Meeting.

27. Delegation of authority to the Board of Directors, with shareholders' preferential subscription rights waived, to increase the Company's share capital through an issue reserved for certain categories of investors as part of an "At-the-market" or "ATM" equity financing program

The General Meeting, voting under the quorum and majority conditions required for extraordinary meetings, after having taken note of the report of the Board of Directors and the special report of the Statutory Auditors, in accordance with Articles L. 225-138 and L. 225-129-2 of the French

Commercial Code, delegates to the Board of Directors, with the option of sub-delegation under the conditions provided for by law, its authority to decide to increase the share capital, on one or more occasions, in France and/or abroad, in the proportions and at the times it sees fit, by a maximum nominal amount of EUR 1,500,000, it being specified that the total nominal amount of the capital increases likely to result from the present resolution, as well as from the 21st to 29th resolutions submitted to the present General Meeting, may not exceed the overall ceiling of EUR 3,000,000 set in the 21st resolution, through the issue of ordinary shares in the form of American Depositary Shares or American Depositary Receipts of the Company.

The General Meeting resolves to cancel the shareholders' preferential subscription rights to the shares that may be issued pursuant to this resolution and to reserve the right to subscribe for them to:

- any credit institution or any investment services provider, French or foreign, or any foreign institution with equivalent status, acting within the framework of an ATM program set up by the Company (or any equity financing program of the same nature that may be substituted for it) and providing, within this framework, for the subscription of securities issued by the Company.

If subscriptions do not absorb the entire issue of shares under this resolution, the Board of Directors may limit the issue to the amount of subscriptions, provided that this amount reaches at least three-quarters of the issue decided upon, and/or freely allocate all or part of the unsubscribed shares among the persons of its choice.

The General Meeting resolves that the Board of Directors shall have full powers, with the option of sub-delegation under the conditions provided for by law, to implement this resolution, and in particular to determine the list of beneficiary(ies), within the category(ies) of beneficiaries mentioned above in favor of

whom the preferential subscription right has been waived.

In particular, it may determine the number of securities to be issued to each beneficiary and set, in the light of the indications contained in its report, the subscription price of the said securities and their dividend entitlement date, which may be retroactive, it being specified that the issue price of the ordinary shares must be at least equal to:

- either the closing price of the Company's shares on the regulated market Euronext Paris during the last trading session prior to its determination;
- or the volume-weighted average (in the central order book and excluding off-market blocks) of the Company's share price on the regulated market of Euronext Paris during the last 3 trading sessions preceding the setting of the issue price, this average being able to be corrected, if necessary, to consider differences in the date of dividend entitlement;

possibly reduced by a maximum discount of 20%;

In accordance with the provisions of Article L. 225-138 of the French Commercial Code, the Board of Directors will prepare a report to the next Ordinary General Meeting describing the final terms of the transactions carried out under this resolution.

The delegation thus granted to the Board of Directors is valid for a period of 18 months from the date of this Meeting.

28. Delegation of authority to the Board of Directors to issue common shares of the Company and/or securities convertible to common shares to be issued by the Company in the event of a public exchange offer initiated by the Company, with shareholders' preferential subscription rights waived

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, after having read the Board of Directors' Report and the Statutory

Auditors' special report, and voting in accordance with Articles L. 225-129 *et seq.* of the French Commercial Code, and notably Articles L. 225-129-2, L. 22-10-54 and L. 228-91 *et seq.* of the said Code:

- terminates, with immediate effect, the unused portion of the delegation granted by the nineteenth resolution of the General Shareholders' Meeting of June 25, 2021,
- delegates to the Board of Directors, for a period of 26 months from the date of this General Shareholders' Meeting, the authority to decide, defined in the 22nd resolution above, to issue common shares of the Company and/or securities convertible to common shares to be issued immediately or in the future by the Company in compensation for securities tendered in a public offering that has an exchange component initiated in France or abroad in accordance with local regulations by the Company on the securities of a company whose shares are admitted for trading on one of the regulated stock markets listed in Article L. 22-10-54 mentioned above, and decides, as and when necessary, to waive, in favor of the holders of such securities, the shareholders' preferential subscription rights to common shares and securities to be issued.

The General Shareholders' Meeting duly notes that this delegation includes the shareholders' waiver of their preemptive rights to subscribe for common shares to which the marketable securities issued on the basis of this delegation may entitle them.

The cap for the nominal amount of the immediate or future capital increase resulting from all issues carried out by virtue of this delegation of authority is set at EUR 3,000,000 on the understanding that (i) such cap is shared with the ceiling set forth in the 22nd resolution and deducted from it and (ii) the nominal amount of all capital increases likely to be made under this resolution as well as under the 21st to 29th resolutions submitted to

this General Shareholders' Meeting cannot exceed the overall ceiling of EUR 3,000,000 set in the 21st resolution and lastly, that (iii) the cap is set excluding the nominal amount of any common Company shares that may be issued as a result of legal and contractual adjustments made to protect holders of rights attached to securities convertible to common shares.

The maximum nominal value of such debt securities may not exceed EUR 150,000,000 or the equivalent of that amount on the date of the decision to issue, it being understood that (i) such amount does not include redemption premiums above par, if any, and that (ii) it is an overall ceiling covering all debt securities that may be issued under the 21st to 29th resolutions submitted to this General Shareholders' Meeting, and that, consequently, the par value of the debt securities liable to be issued pursuant to the above resolutions may not be greater than that ceiling. This ceiling is independent from the debt securities whose issue would be decided on or authorized by the Board of Directors in accordance with Article L. 228-40 of the French Commercial Code.

The General Shareholders' Meeting decides that the Board of Directors shall have full authority to implement the public offers listed in this resolution, and in particular to:

- determine the parity ratios as well as the amount of the cash bonus to be paid, where applicable;
- record the number of securities contributed to the exchange;
- determine the dates, terms, and conditions of the issue, and particularly the price and entitlement date, which may be retroactive, new common shares or marketable securities providing access to common shares of the Company, where applicable, and, if necessary, modify the terms and conditions of securities issued under this resolution during the term of the securities concerned and in compliance with applicable legal and regulatory provisions;

- record the difference between the new common shares' issue price and their par value as a liability on the balance sheet in a "share premium" line item;
- assign any of the fees and costs incurred from the authorized transaction to said "share premium" account, where applicable;
- generally, adopt all useful measures and enter into any agreement to ensure that the authorized transaction is successful, record the resulting capital increases and make any corresponding amendments to the articles of incorporation.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the power that is granted to it under this resolution.

29. Authorization for the Board of Directors to issue, with existing shareholders' preferential subscription rights waived, common shares and/or securities convertible to common shares to be issued, to be used as payment for in-kind contributions to the Company consisting of equity securities or other securities convertible to shares

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary Shareholders' Meetings, having reviewed the Board of Directors' Report and the Statutory Auditors' special report, and ruling in accordance with Articles L.225-147, L.22-10-53 and Articles L. 228-91 et seq. of the French Commercial Code:

- terminates, with immediate effect, the unused portion of the delegation of authority granted by the twentieth resolution of the General Shareholders' Meeting of June 25, 2021,
- delegates to the Board of Directors the authority to issue common shares of the

Company or marketable convertible to common shares to be issued immediately or in the future by the Company to pay for contributions in kind granted to the Company and consisting of shares of the Company's stock and/or marketable securities convertible into shares where the provisions of Article L. 22-10-54 are not applicable, and to decide to eliminate the shareholder preferential subscription rights of the common shares and marketable securities thus issued for those holding securities or marketable securities, the subject of the contribution in kind, as and when necessary, based on the report on capital contributions of the auditor(s) mentioned in paragraph 1 and 2 of Article L.225-147 mentioned above, within the terms and conditions set forth in the 21st resolution above, for a 26-month period starting from the day of this General Shareholders' Meeting.

The maximum nominal amount of the immediate or future capital increase resulting from all of the issues carried out under this delegation is set at 10% of the Company's capital (existing on the date of this General Shareholders' Meeting), provided that (i) a portion of this ceiling is deducted from the EUR 3,000,000 ceiling defined in the 22nd resolution, and that (ii) the total nominal amount of capital increases likely to result from this resolution, as well as the 21st to 29th resolutions submitted to this General Shareholders' Meeting, may not exceed the total ceiling of EUR 3,000,000 set forth in the 21st resolution.

The maximum nominal value of such debt securities may not exceed EUR 150,000,000 or the equivalent of that amount on the date of the decision to issue, it being understood that (i) such amount does not include redemption premiums above par, if any, and that (ii) it is an overall ceiling covering all debt securities that may be issued under the 21st to 29th resolutions submitted to this General Shareholders' Meeting, and that, consequently, the par value of the debt securities liable to be issued pursuant to the

above resolutions may not be greater than that ceiling. This ceiling is independent from the debt securities whose issue would be decided on or authorized by the Board of Directors in accordance with Article L. 228-40 of the French Commercial Code.

The General Shareholders' Meeting duly notes that this delegation includes the shareholders' waiver of their preemptive rights to subscribe for common shares to which the marketable securities issued on the basis of this delegation may entitle them.

The Board of Directors shall have full authority to implement this resolution, in particular to:

- decide on the assessment of contributions and any potential grants of special benefits, based on the capital contributions auditor(s) report mentioned in paragraph 1 and 2 of Article L.225-147 of the French commercial code mentioned above;
- approve the list of capital securities or marketable securities contributed to the exchange, determine the parity ratios as well as the amount of the cash bonus to be paid, where applicable;
- approve the number of securities to be issued in compensation for the contributions as well as the entitlement date of shares to be issued, which may potentially be retroactive, and marketable securities to be issued providing immediate or future access to existing shares or shares to be issued by the Company, where applicable;
- charge the fees and expenses incurred by the issues to the amount of corresponding premiums and deduct the amount necessary from this amount to increase the legal reserve to one-tenth of share capital;
- record the final completion of the capital increases carried out under this delegation, make any corresponding amendments to the articles of incorporation, carry out any formalities and declarations and require any authorizations that may prove

necessary in order to complete these contributions.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the powers that are granted to it under this resolution.

30. Delegation of authority to the Board of Directors to increase the Company's capital by incorporating reserves, profits, or premiums

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, after having read the Board of Directors' report and voting in accordance with Article L. 225-129-2, L.225-130 and L.22-10-50 of the French Commercial Code:

- terminates, with immediate effect, the unused portion of the delegation of authority granted by the twenty-first of the General Shareholders' Meeting of June 25, 2021,
- delegates to the Board of Directors, for a period of 26 months from the date of this General Shareholders' Meeting, the authority to decide to increase the share capital one or more times, at the time(s) it sets forth and according to the terms and conditions it determines, by successively or simultaneously incorporating reserves, profits, or premiums into the share capital, or any other amounts whose capitalization would be permitted by Law and under the Company's articles of incorporation, followed by creating and allocating bonus shares or by raising the par value of existing common shares, or by using a combination of these two methods.

The Board of Directors shall have the option to decide that fractional rights will neither be traded nor sold and that the corresponding securities will be sold. The amounts arising

from the sale shall be allocated to the rights holders within the time frame set forth by regulations.

The maximum nominal amount of the immediate or future capital increase resulting from all of the issues carried out under this delegation is set at EUR 1,300,000 provided that this ceiling is set (i) without taking into account the nominal amount of common shares of the Company to be issued in the future for legal or contractual adjustments made to protect those holding rights attached to the marketable securities providing access to common shares, and (ii) autonomously and separately from the capital increase ceilings resulting from issues of common shares or marketable securities authorized under other resolutions submitted to this General Shareholders' Meeting.

The Board of Directors shall have full authority to implement this resolution, and in generally adopt any measure or fulfill any formalities required to successfully complete each capital increase.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the powers that are granted to it under this resolution.

31. Delegation of authority to the Board of Directors to carry out capital increases reserved for employees participating in an Erytech Pharma group savings plan, with shareholders' preferential subscription rights waived

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, after having read the Board of Directors' report prepared in accordance with Articles L. 225-102 and L. 225-129-6 of the French Commercial Code, the Statutory Auditors' special report and the provisions of Articles L. 225-129-6, L. 225-138 I and II and L. 225-138-1 of the French Commercial Code:

- authorizes the Board of Directors to carry out a capital increase of the Company by issuing common shares reserved for employees of the Company and its affiliates within the meaning of Article L. 225-180 of the French Commercial Code, participating in a company savings plan. This capital increase will be carried out under the terms and conditions set forth in Articles L. 3332-18 *et seq.* of the French Labor Code.
- delegates full authority to the Board of Directors to decide upon and carry out this capital increase one time under the terms and conditions set forth above, to define the terms and conditions that the beneficiaries must meet, with these terms and conditions being able to include employee seniority conditions, provided that the required period does not exceed six months, to set the terms and conditions in which the shares shall be issued and paid up, to amend the articles of association, and generally take any additional steps that may be required;

As a result, the General Shareholder's Meeting:

- decides to eliminate shareholders' preferential subscription rights for new shares to be issued to employees of the Company and its affiliates who are members of a company savings plan;
- decides that the capital increase authorized under this resolution shall be carried out within one year starting from this General Meeting.

- decides that the issue price for new shares shall be set by the Board of Directors by referencing the Company's share prices on the Euronext Paris stock market, with the understanding that this price may not exceed the average price over the past twenty (20) trading sessions preceding the day of the Board of Directors' decision to set the opening date for the subscription period, nor be more than 30% lower than this average price, or 40% when the lock-up period defined by the company savings plan is greater than or equal to 10 years;

- limits the maximum nominal amount of the capital increase that may be carried out by the Board of Directors, which may not increase the amount of said employees' equity investment (including the equity investment already held) by more than 3% of the total amount of share capital on the day that the Board of Directors decides to implement this authorization;

- decides that the new shares shall be subject to all provisions of the articles of incorporation, shall be combined with old shares and shall bear rights as of the first day of the year during which the capital increase took place;

The shareholders duly note that this resolution has been proposed to comply with the provisions of Article L. 225-129-6 of the French Commercial Code in respect to the authorizations granted under the 21st to the 29th resolutions above and the 32nd and 33rd resolution below.

32. Authorization for the Board of Directors to award bonus shares, existing or to be issued, with existing shareholders' preferential subscription rights waived, to corporate officers or employees of the Company or related companies

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, after having read the Board of Directors' Report and the Statutory Auditors' special report:

- terminates, with immediate effect, the unused portion of the delegation of authority granted by the twenty-third resolution of the General Shareholders' Meeting of June 25, 2021,
- authorizes the Board of Directors to grant existing common shares or common bonus shares to be issued by the Company one or

more times and under the terms and conditions that it determines, within the limits set under this authority, in accordance with Articles L.225-197-1 *et seq.* and L. L.22-10-59 *et seq.* of the French Commercial Code, and under the terms and conditions below.

The beneficiaries must be employees of the Company, or French companies or groups that are related within the meaning of Article L. 225-197-2 of the French Commercial Code, or corporate officers of the Company, or of related companies or groups related to it, and which fulfill the terms and conditions listed in Article L. 225-197-1 II, or certain categories among them.

If the shares are granted to executive corporate officers referred to in Article L. 225-197-1 II of the French Commercial Code, they may only be granted as per the terms and conditions of Article L. 22-10-60 of said Code.

This authorization is granted for a 38-month period starting from the day of this General Shareholders' Meeting.

The total number of common bonus shares granted under this resolution may not exceed 800,000 shares, provided that the total nominal amount of capital increases likely to result from this resolution may not exceed the ceiling of 1,500,000 common shares for all of the issues likely to be carried out under the 32nd to 34th resolutions submitted to this General Shareholders' Meeting.

The General Shareholders' Meeting decides that the granting of these shares to their beneficiaries shall become final for all, or part of the shares granted:

- at the end of a vesting period defined by the Board of Directors, which may not be less than one year;
- potentially at the end of a minimum retention period by the beneficiaries starting from the final allocation of the shares, the duration of which would be defined by the Board of Directors.

In accordance with the Law, the total duration of vesting periods, and retention periods where applicable, for shares may not be less than two years.

The General Shareholders' Meeting decides that, in the event of the disability of the beneficiary meeting the conditions set forth by Law, the final allocation of the shares may take place before the end of the vesting period.

Existing shares that may be allocated under this resolution must be acquired by the Company as part of a share buyback program authorized by the 19th resolution submitted to this General Shareholders' Meeting under Article L.22-10-62 of the French Commercial Code, or any share buyback program applicable previously or subsequently.

The General Shareholders' Meeting takes note of and decides, where applicable, that this authorization shall entail the waiver by shareholders (i) of their preferential subscription rights to common shares, which will be issued when the shares undergo final allocation, (ii) of their entitlement to bonus shares based on this authorization and (iii) of any entitlement to the amount of reserves, earnings or premiums that the new shares shall be allocated to, where applicable, for those receiving allocations of existing common shares or common shares to be issued.

The General Shareholders' Meeting confers all powers to the Board of Directors, which may be assisted by a committee comprising members of its choice, in order to carry out the following, within the limits set forth above:

- set the terms and conditions and the criteria for granting common shares, where applicable, as well as the performance conditions to be met in order to make the grant final, if applicable;
- determine if the bonus shares granted are shares to be issued or existing shares;

- establish the dates on which the grants of bonus shares will take place, subject to legal conditions and limits;
- decide the entitlement date of the newly issued common shares, which may be retroactive;
- determine the beneficiary's identity, the number of common shares granted to each of them, the terms, and conditions of granting common shares, and in particular, the vesting periods and retention periods of the bonus shares;
- decide on one or more capital increases of the Company resulting from granting bonus shares to be issued by the Company;
- decide the terms and conditions under which the number of common shares granted shall be adjusted; and
- generally, sign any agreements, prepare any documents, carry out any formalities and make any necessary declarations with the relevant bodies and do anything else that may be required.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the power that is granted to it under this resolution.

The Board of Directors will inform the General Shareholders' Meeting of any allocations made under this resolution on a yearly basis, in accordance with Article L.225-197-4 of the French Commercial Code.

33. Authorization for the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies in the Erytech Pharma group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, after having read the Board of Directors' Report and the Statutory Auditors' special report,

- terminates, with immediate effect, the unused portion of the delegation of authority granted by the twenty fourth resolution of the General Shareholders' Meeting of June 25, 2021;
- authorizes the Board of Directors to grant Company stock options once or several times under the terms and conditions below, in accordance with Articles L. 225-177 et seq. and L.22-10-56 et seq. of the French Commercial Code.

The beneficiaries must be employees or corporate officers of the Company or of French or foreign companies or groups related to the Company in the meaning of Article L. 225-180 of the French Commercial Code, or certain categories among them. The Board of Directors may grant the options to all or some of these people.

This authorization is granted for a 38-month period starting from the day of this General Shareholders' Meeting.

Each option shall confer entitlement to subscribe or purchase a new or existing common share, as appropriate.

The total number of share options that may be granted under this resolution may not confer entitlement to subscribe or purchase a number of shares in excess of 1,200,000 shares, provided that the total nominal amount of capital increases likely to result

from this resolution may not exceed (i) the 1,500,000 share ceiling for all of the issues likely to be carried out under the 32nd to 34th resolutions submitted to this General Shareholders' Meeting, and lastly (ii) that these ceilings are set without taking into account the nominal amount of common shares of the Company that may be issued in the future for legal or contractual adjustments made to protect those holding rights attached to the securities convertible to common shares.

The shares that may be obtained by exercising stock options granted under this resolution must be acquired by the Company as part of a share buyback program described in the 19th resolution submitted to this General Shareholders' Meeting pursuant to Article L.22-10-62 of the French Commercial Code, or any share buyback program applicable previously or subsequently.

The exercise price of the options granted under this resolution shall be set by the Board of Directors according to the following terms and conditions:

- the stock options' exercise price may not be less than 95% of the Company's average share price on the regulated Euronext Paris stock market over the twenty trading sessions prior to the day the options were granted. In addition,
- the stock option exercise price may not be less than 95% of the Company's average purchase price of the shares held by the Company under the share buyback program authorized in the 19th resolution submitted to this to this General Shareholders' Meeting under article L.22-10-62 of the French Commercial Code or any share buyback program applicable previously or subsequently.

The options allocated must be exercised within 10 years from the day they are granted by the Board of Directors. The Company's Extraordinary General Shareholders' Meeting is authorized to extend the aforementioned 10-year time frame at any time.

The General Shareholders' Meeting takes note of and decides that, for stock option beneficiaries, this authorization includes the shareholders' express waiver of their preferential subscription rights to the shares that will be issued when these options are exercised, if needed.

The General Shareholders' Meeting confers all powers to the Board of Directors, which may be assisted by a committee comprising members of its choice, in order to carry out the following, within the limits set forth above:

- establish the dates on which the options will be granted, subject to legal conditions and limits;
- determine the list of option beneficiaries, the number of options allocated to each of them, terms and conditions for the grant as well as for exercising the options;
- set the conditions for exercising the options, and in particular, limit, restrict or prohibit (a) exercising options (notably define the performance conditions to be met, where applicable) or (b) sell the shares obtained by exercising the options, during certain periods or starting when certain events take place. This decision may (i) pertain to all or part of the options and (ii) concern all or part of the beneficiaries;
- decide on the conditions in which the price and/or number of shares to subscribe or purchase will be adjusted in cases provided for by Law;
- more generally, enter into all agreements, prepare all documents, record capital increases following the exercise of options, amend the articles of incorporation accordingly where necessary, carry out all formalities and declarations with all bodies and take all other necessary action.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief

Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the power that is granted to it under this resolution.

The Board of Directors shall inform the General Shareholders' Meeting of transactions carried out under this resolution every year.

34. Authorization for the Board of Directors to issue share subscription warrants, with existing shareholders' preferential subscription rights waived, to corporate officers or employees of the Company or Erytech Pharma group companies

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary Shareholders' Meetings, and having reviewed the Board of Directors' Report and the Statutory Auditors' special report:

- terminates, with immediate effect, the unused portion of the delegation given by the General Shareholders' Meeting of June 25, 2021, in its twenty-fifth resolution;
- authorizes the Board of Directors to decide to increase the share capital once or several times in the proportions and at the times that it deems fit, by issuing warrants under the terms and conditions below and in accordance with Articles L. 225-129 to L. 225-129-6, L.22-10-49, L. 225-138 and L. 228-91 et seq. of the French Commercial Code.

The beneficiaries must be employees, consultants, or corporate officers of the Company or of French or foreign companies or groups related to it in the meaning of Article L. 225-180 of the French Commercial Code, or certain categories among them.

The total number of options that may be granted under this resolution may not confer entitlement to subscribe or purchase a number of shares in excess of 200,000 shares, provided that the total nominal amount of capital increases likely to result from this resolution may not exceed (i) the 1,500,000

share ceiling for all of the issues likely to be carried out under the 32nd to 34th resolutions submitted to this General Shareholders' Meeting, and lastly (ii) that these ceilings are set without taking into account the nominal amount of common shares of the Company that may be issued in the future for legal or contractual adjustments made to protect those holding rights attached to the securities convertible to common shares.

This authorization is granted for an 18-month period starting from the day of this General Shareholders' Meeting.

The General Shareholders' Meeting takes note of and decides, where applicable, that this authorization shall act as an express waiver by shareholders of their preferential subscription rights to which the warrants issued entitle, for those who hold warrants issued under this resolution.

The General Shareholders' Meeting confers all powers to the Board of Directors, which may be assisted by a committee comprising members of its choice, in order to carry out the following, within the limits set forth above:

- establish the list of beneficiaries within the category of beneficiaries previously mentioned, for which preferential subscription rights have been eliminated;
- approve the features, amounts and terms and conditions of any issue, as well as terms and conditions for paying up securities issued, provided that a warrant shall entitle the right to subscribe a Company share; notably determine the number of warrants to issue for each beneficiary and set the subscription price and entitlement date for those warrants according to the information contained in its report, provided that the amount owed to the Company for each of the shares issued under this delegation shall be at least equal to the volume weighted average closing share price recorded during a period of no less than five consecutive trading days to no more than

thirty consecutive trading days from the thirty trading days prior to setting the subscription price, potentially discounted by a maximum of 5% at the time the warrants are granted.

The Board of Directors may, within the limits that it sets in advance, delegate to the Chief Executive Officer or, with the agreement of the latter, to one or more Chief Operating Officers, the power that is granted to it under this resolution.

The Board of Directors shall inform the General Shareholders' Meeting of transactions carried out under this resolution every year.

35. Powers for carrying out formalities

The General Shareholders' Meeting grants all powers to the person(s) holding copies or extracts from these meeting minutes to carry out any and all legal formalities.

SUMMARY OF CURRENT FINANCIAL DELEGATIONS

| Date of General Shareholders' Meeting | Nature of authorization | Maximum nominal amount of the capital increase or issue of marketable securities | Overall nominal ceiling | Duration | Utilization | Maximum remaining nominal amount |
|---------------------------------------|---|--|---|-------------------------|--|--|
| 6/25/2021 | Share capital increase through the issue of common shares and/or securities convertible to common shares, with preferential subscription rights maintained (13th resolution) | EUR 2,000,000 EUR 150,000,000 (debt securities) | | 26 months 8/25/2023 | None | EUR 2,000,000 EUR 150,000,000 (debt securities) |
| 6/25/2021 | Share capital increase through the issue of common shares and/or securities convertible to common shares, with preferential subscription rights waived by public offering other than the public offerings referred to in section 1° of article L.411-2 of the Monetary and Financial Code (14th resolution) | EUR 1,500,000** EUR 150,000,000 (debt securities) | | 26 months 8/25/2023 | None | EUR 1,192,156.80 EUR 150,000,000 (debt securities) |
| 6/25/2021 | Share capital increase through the issue of common shares and/or securities convertible to common shares, with preferential subscription rights waived by public offering referred to in section 1° of Article L.411-2 of the French Monetary and Financial Code (15th resolution) | 20% of the share capital (per 12-month period), limited to EUR 1,500,000** EUR 150,000,000 (debt securities) | | 26 months 8/25/2023 | None | 20% of the share capital (per 12-month period), limited to EUR 1,192,156.80 EUR 150,000,000 (debt securities) |
| 6/25/2021 | Authorization to set the price, in the case of an issue with preferential subscription rights waived, of common shares and/or marketable securities convertible to common shares (16th resolution) | 10% of the share capital per year | EUR 2,000,000* EUR 150,000,000 (Debt securities) | 26 months 8/25/2023 | None | N/A |
| 6/25/2021 | Authorization to increase in the number of shares to be issued in the event of a capital increase, with preferential subscription rights waived or maintained (17th resolution) | 15% of the initial issue limited to the ceiling specified in the resolution in application of which the issue has been | | 26 months 8/25/2023 | None | N/A |
| 6/25/2021 | Capital increase with preferential subscription rights waived for certain categories of investors**** (18th resolution) | EUR 1,500,000** EUR 150,000,000 (debt securities) | | 18 months 12/25/2022 | EUR 307,843.20 (CEO decision of December 14, 2021) | EUR 1,192,156.80 EUR 150,000,000 (debt securities) |
| 6/25/2021 | Issue of common shares and/or marketable securities convertible to common shares in the case of a public exchange offering initiated by the Company, with preferential subscription rights waived (19th resolution) | EUR 1,500,000** EUR 150,000,000 (debt securities) | | 26 months 8/25/2023 | None | EUR 1,192,156.80 EUR 150,000,000 (debt securities) |
| 6/25/2021 | Issue of common shares and/or marketable securities convertible to common shares, to compensate for contributions in kind granted to the Company and consisting of capital securities or marketable securities convertible to capital (20th resolution) | 10% of the capital of the company, limited to EUR 1,500,000** EUR 150,000,000 (debt securities) | | 26 months 8/25/2023 | None | EUR 1,192,156.80 EUR 150,000,000 (debt securities) |

| Date of General Shareholders' Meeting | Nature of authorization | Maximum nominal amount of the capital increase or issue of marketable securities | Overall nominal ceiling | Duration | Utilization | Maximum remaining nominal amount |
|---------------------------------------|--|--|-------------------------|-------------------------|--|--|
| 6/25/2021 | Capital increase by incorporation of reserves, profits, or premiums (21st resolution) | EUR 1,300,000*** | | 26 months 8/25/2023 | None | EUR 1,300,000 |
| 6/25/2021 | Capital increase by the issue of shares reserved for employees enrolled in a company savings plan (22nd resolution) | 3% of share capital*** | | 12 months 6/25/2022 | None | N/A |
| 6/25/2021 | Authorization for the Board of Directors to award bonus shares, existing or to be issued, with shareholders' preemptive subscription rights waived, to corporate officers or employees of the Company or related companies (23rd resolution) | 400,000 shares | | 38 months 8/25/2024 | 231,000 shares (Board of Directors of July 27, 2021), 93,331 shares (CEO decision of December 16, 2021) | 103,469 shares (€10,346.9)***** |
| 6/25/2021 | Authorization for the Board of Directors to grant share subscription and/or purchase options for corporate officers and employees of the Company and ERYTECH Pharma Group companies (24th resolution) | 700,000 shares | 900,000 shares | 38 months 8/25/2024 | 377,550 shares (Board of Directors of July 27, 2021), 149,000 shares (CEO decision of December 16, 2021) | 237,650 shares (€23,765)***** 65,869 shares (€6,586.90) |
| 6/25/2021 | Authorization for the Board of Directors to issue detachable share subscription warrants, with shareholders' preemptive subscription rights waived, for corporate officers and employees of the Company or companies in the Erytech Pharma Group (25th resolution) | 100,000 shares | | 18 months 12/25/2022 | 75,250 shares (Board of Directors of July 27, 2021) | 24,750 shares (€2,475) |

* EUR 2,000,000 common overall ceiling to the 13th to 20th resolutions of the General Meeting of June 25, 2021

** EUR 1,500,000 common overall ceiling set in the 14th resolution of the General Meeting of June 25, 2021

*** Ceiling independent of the overall ceiling of EUR 2,000,000 applicable to other financial delegations

****The categories of persons referred to in the 18th resolution of the General Meeting are as follows

- i. individuals or legal entities, including companies, trusts or investment funds or other investment vehicles of any kind, under French or foreign law, that habitually invest in the pharmaceutical, biotechnology or medical technology sectors; and/or
- ii. French or foreign companies, institutions or entities, whatever their form, carrying out a significant part of their activities in the pharmaceutical, cosmetics, chemical or medical devices and/or technologies sectors or research in these areas; and/or
- iii. French or foreign investment services providers, or any foreign institution with an equivalent status, likely to guarantee the realization of an issue intended to be placed with the persons referred to in (i) and/or (ii) above and, within this framework, to subscribe for the securities issued.

*****After deduction of 27,800 shares declared lapsed following the departure of employees

*****After deduction of 64,200 shares declared lapsed following the departure of employees

FINANCIAL DELEGATIONS PROPOSED TO THE COMBINED GENERAL SHAREHOLDERS' MEETING OF JUNE 24, 2022

| Date of General Shareholders' Meeting | Nature of authorization | Maximum nominal amount of the capital increase or issue of marketable securities representing debt securities resulting from the issue | Overall nominal ceiling | Duration and Expiration date |
|---------------------------------------|---|--|--|------------------------------|
| 6/24/2022 | Share capital increase through the issue of common shares and/or securities convertible to common shares, with preferential subscription rights maintained (21st resolution) | EUR 3,000,000 EUR 150,000,000 (debt securities) | | 26 months 8/24/2024 |
| 6/24/2022 | Share capital increase through the issue of common shares and/or securities convertible to common shares, with preferential subscription rights waived by public offering other than the public offerings referred to in section 1° of article L.411-2 of the Monetary and Financial Code (22nd resolution) | EUR 3,000,000 EUR 150,000,000 (debt securities) | | 26 months 8/24/2024 |
| 6/24/2022 | Share capital increase through the issue of common shares and/or securities convertible to common shares, with preferential subscription rights waived by public offering referred to in section 1° of Article L.411-2 of the French Monetary and Financial Code (23rd resolution) | 20% of the share capital (per 12-month period), limited to EUR 3,000,000 EUR 150,000,000 (debt securities) | | 26 months 8/24/2024 |
| 6/24/2022 | Authorization to set the price, in the case of an issue with preferential subscription rights waived, of common shares and/or marketable securities convertible to common shares (24th resolution) | 10% of the share capital per year | EUR 3,000,000 EUR 150,000,000 (Debt securities) | 26 months 8/24/2024 |
| 6/24/2022 | Authorization to increase in the number of shares to be issued in the event of a capital increase, with preferential subscription rights waived or maintained (25th resolution) | 15% of the initial issue limited to the ceiling specified in the resolution in application of which the issue has been determined | | 26 months 8/24/2024 |
| 6/24/2022 | Capital increase with preferential subscription rights waived for certain categories of investors (26th resolution) | EUR 3,000,000 EUR 150,000,000 (debt securities) | | 18 months 12/24/2023 |
| 6/24/2022 | Capital increase with preferential subscription rights waived for certain categories of persons meeting specified characteristics within the framework of an "At-the-market" equity financing program (27th resolution) | EUR 1,500,000 EUR 150,000,000 (debt securities) | | 18 months 12/24/2023 |
| 6/24/2022 | Issue of common shares and/or marketable securities convertible to common shares in the case of a public exchange offering initiated by the Company, with preferential subscription rights waived (28th resolution) | EUR 3,000,000 EUR 150,000,000 (debt securities) | | 26 months 8/24/2024 |
| 6/24/2022 | Issue of common shares and/or marketable securities convertible to common shares, to compensate for contributions in kind granted to the Company and consisting of capital securities or marketable securities convertible to capital (29th resolution) | 10% of the capital of the company, limited to EUR 3,000,000 EUR 150,000,000 (debt securities) | | 26 months 8/24/2024 |

| Date of General Shareholders' Meeting | Nature of authorization | Maximum nominal amount of the capital increase or issue of marketable securities representing debt securities resulting from the issue | Overall nominal ceiling | Duration and Expiration date |
|---------------------------------------|--|--|-------------------------|--|
| 6/24/2022 | Capital increase by incorporation of reserves, profits, or premiums (30th resolution) | EUR 1,300,000 | | 26 months 8/24/2024 |
| 6/24/2022 | Capital increase by the issue of shares reserved for employees enrolled in a company savings plan (31st resolution) | 3% of share capital | | The Board of Directors proposes rejection of this resolution |
| 6/24/2022 | Authorization for the Board of Directors to award bonus shares, existing or to be issued, with shareholders' preemptive subscription rights waived, to corporate officers or employees of the Company or related companies (32nd resolution) | 800,000 shares | | 38 months 8/24/2025 |
| 6/24/2022 | Authorization for the Board of Directors to grant share subscription and/or purchase options for corporate officers and employees of the Company and ERYTECH Pharma Group companies (33rd resolution) | 1,200,000 shares | 1,500,000 shares | 38 months 8/24/2025 |
| 6/24/2022 | Authorization for the Board of Directors to issue detachable share subscription warrants, with shareholders' preemptive subscription rights waived, for corporate officers and employees of the Company or companies in the Erytech Pharma Group (34th resolution) | 200,000 shares | | 18 months 12/24/2023 |

PROFESSIONAL REFERENCES OF PROPOSED DIRECTORS



JEAN-PAUL KRESS M.D.

CHAIRMAN OF THE BOARD & DIRECTOR
MEMBER OF THE REMUNERATIONS AND APPOINTMENT COMMITTEE

Age: 56 years old

Degree: M.D. graduated from the *Faculté Necker-Enfants Malades* in Paris and holds an advanced degree in pharmacology and immunology from *École Normale Supérieure* in Paris.

PROFESSIONAL EXPERIENCE

Jean-Paul Kress, M.D. has served as the Company's Chairman of the Board of Directors since June 2019. Dr. Kress has served as the Chief Executive Officer of MorphoSys AG since September 2019. He previously served as President and Chief Executive Officer of Syntimmune Inc. (Cambridge, United States) until November 2018.

Prior to joining Syntimmune, Dr. Kress served as Executive Vice President of International and Head of Global Therapeutic Operations at Biogen Inc. He previously served as a member of the board of directors of Sarepta Therapeutics, Inc. from September 2015 to June 2017 and as Senior Vice President, Head of North America at Sanofi Genzyme.

From July 2011 to September 2015, Dr. Kress served as President and Chief Executive Officer of Sanofi Pasteur MSD, one of the leading European vaccine companies. Prior to then, Dr. Kress worked at Gilead, Abbvie and Eli Lilly in senior commercial and business development roles in the United States and in Europe.

OTHER CURRENT MANDATES AND FUNCTIONS

- Chief Executive Officer of MorphoSys

OTHER OFFICES AND POSITIONS HELD OUTSIDE THE COMPANY OVER THE PAST FIVE YEARS AND NOW TERMINATED

- President and Chief Executive Officer of Syntimmune Inc
- Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen Inc
- Senior Vice President, Head of North America at Sanofi Genzyme
- Director of Sarepta Therapeutics
- Director of Quantum Genomics

NUMBER OF SHARES HELD AS OF APRIL 30, 2022

- 59,123 Stock Options₂₀₁₉
- 30,000 Stock Options₂₀₂₀
- 27,000 Stock Options₂₀₂₁



GIL BEYEN

CHIEF EXECUTIVE OFFICER
DIRECTOR

Age: 61 years old

Degree: M.S. in Bioengineering from the University of Leuven (Belgium) and an M.B.A. from the University of Chicago.

PROFESSIONAL EXPERIENCE

Gil Beyen has served as the Company's Chief Executive Officer since May 2013 and as Chairman of the Board of Directors of the Company from May 2013 until June 2019. Prior to his appointment as Chief Executive Officer, he assisted the Company in a consulting role as of 2012 and also served as Chairman of the supervisory board from August 2012 until May 2013. Gil Beyen was co-founder and Chief Executive Officer of TiGenix (NYSE Euronext: TIG BB) for 12 years. Before founding TiGenix, he served as the head of the Life Sciences division of Arthur D. Little, an international management consulting firm, in Brussels.

OTHER CURRENT MANDATES AND FUNCTIONS

- Director of AXXIS V&C BV
- Director of Novadip SA
- President of ERYTECH Pharma Inc.

OTHER OFFICES AND POSITIONS HELD OUTSIDE THE COMPANY OVER THE PAST FIVE YEARS AND NOW TERMINATED

- Manager of Gil Beyen BVBA
- Director of Waterleau NV

NUMBER OF SHARES HELD AS OF APRIL 30, 2022

- 4,840 ordinary shares
- 60,000 BSPCE₂₀₁₄
- 31,321 free shares AGA₂₀₁₉
- 28,125 free shares AGA₂₀₂₀
- 33,000 free shares AGA₂₀₂₁
- 18,200 Stock Options₂₀₁₈
- 105,000 Stock Options₂₀₁₉
- 105,000 Stock Options₂₀₂₀
- 115,500 Stock Options₂₀₂₁



PHILIPPE ARCHINARD Ph. D

DIRECTOR
CHAIRMAN AND MEMBER OF THE REMUNERATIONS AND APPOINTMENT COMMITTEE
MEMBER OF THE AUDIT COMMITTEE & OF THE CLINICAL STRATEGY COMMITTEE

Age: 62 years old

Degree: Ph.D. in biochemistry from the University of Lyon (France) and completed by Harvard Business School's Program for Management Development (PMD) (United States).

PROFESSIONAL EXPERIENCE

Philippe Archinard, Ph.D. has served as a member of the Company's Board of Directors since 2013 and was previously a member of the supervisory board from 2007 to 2013. Dr. Archinard was appointed Executive Vice-President, Technological Innovation and Scientific Partnerships at Institut Mérieux since January 1, 2021.

Dr. Archinard was Chairman and Chief Executive Officer of Transgene from 2004 until December 2020, after 15 years with bioMérieux, a global biotech company, in various roles including the management of the US subsidiary. Prior to joining Transgene, he served as chief executive officer of Innogenetics N.V., from 2000 to 2004. He has served as a member of bioMérieux's Board of Directors since 2005.

OTHER CURRENT MANDATES AND FUNCTIONS

- Executive Vice-President at Institut Mérieux
- Director of Transgene
- Permanent representative of TSGH on the board of ABL Inc
- Chief executive officer of TSGH
- Director of BioMérieux
- Chairman of BioAster
- Director of NH Theraguix

OTHER OFFICES AND POSITIONS HELD OUTSIDE THE COMPANY OVER THE PAST FIVE YEARS AND NOW TERMINATED

- Permanent representative on the Board of Directors of Synergie Lyon Cancer for Lyonbiopôle
- Chairman of Lyonbiopôle
- Director of CPE Lyon, FPUL representative
- Chairman and Chief Executive Officer of Transgene

NUMBER OF SHARES HELD AS OF APRIL 30, 2022

- 10,300 ordinary shares
- 16,250 BSA₂₀₁₇
- 15,000 BSA₂₀₁₉



LUC DOCHEZ

DIRECTOR
MEMBER OF THE CLINICAL STRATEGY COMMITTEE

Age: 47 years old

Degree: Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an M.B.A. degree from Vlerick Management School (Belgium).

PROFESSIONAL EXPERIENCE

Luc Dochez, Pharm.D. has served as a member of the Company's Board of Directors since 2015. Mr. Dochez is currently Executive Chairman at Vico International BV, K5 Therapeutics and at Primix Bioventures BV. He is also a managing partner at DROIA N.V., a position he has held since October 2018. Prior to then, he served as Chief Executive Officer of Tusk Therapeutics Ltd., a private company focused on developing novel immunoncology products, from March 2015 until its acquisition by Roche in September 2018.

Mr. Dochez has over 15 years of experience in the biotechnology industry. He served as the Chief Business Officer and Senior Vice President of Business Development of Prosenza Holding N.V., a biotechnology company, from November 2008 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015.

Mr. Dochez served as Vice President of Business Development at TiGenix, Director Business Development at Methexis Genomics, and a consultant at Arthur D. Little. Mr. Dochez was a board member of Pharvaris BV, a Dutch company focused on rare diseases, as well as Bioncotech Therapeutics SL, a Spanish oncology company.

OTHER CURRENT MANDATES AND FUNCTIONS

- Executive Chairman and Director of Primix Bioventures BV and General Manager and Director of Primix Invest CommV
- Managing Partner DROIA Genetic Diseases Fund and Partner DROIA Oncology Ventures
- Director of Medilabon CommV
- Director of Cascador Health BV
- Director of Volastra Inc.
- Executive Chairman of Vico International BV and Director of Vico Holding & Therapeutics BV
- Executive Chairman of K5 Therapeutics BV
- Chairman and Director of Montis Biosciences BV
- Director and member of the Remuneration Committee of Quaralis Inc
- Director and member of the Remuneration Committee of Muna Therapeutics
- Director of Alesta TX
- Observer Mahzi Therapeutics

OTHER OFFICES AND POSITIONS HELD OUTSIDE THE COMPANY OVER THE PAST FIVE YEARS AND NOW TERMINATED

- Chief Executive Officer of Tusk Therapeutics SA & Tusk Therapeutics Ltd
- Director of Pharvaris BV
- Executive Director of Vico Holding BV

NUMBER OF SHARES HELD AS OF APRIL 30, 2022

- 16,250 BSA₂₀₁₇
- 15,000 BSA₂₀₁₉
- 13,500 BSA₂₀₂₁



SVEN ANDRÉASSON

DIRECTOR
MEMBER OF THE REMUNERATIONS AND APPOINTMENT COMMITTEE & OF THE AUDIT COMMITTEE

Age: 69 years old

Degree: Bachelor of Science and Business Administration and Finance from Stockholm School of Economics and Business Administration (Sweden).

PROFESSIONAL EXPERIENCE

Sven Andréasson has served as a member of the Company's Board of Directors since 2013 (as representative of Galenos SPRL, the legal entity that held this board seat, and as a natural person since January 2022). Mr. Andréasson has served as Senior Vice President, Corporate Development for Novavax, Inc. (United States), a pharmaceutical company since June 2014.

From 2012 to 2013, he served as Chief Executive Officer of Isconova AB (Uppsala, Sweden), a leading international vaccine adjuvant company acquired by Novavax in 2013, currently operating as Novavax AB. Prior to his role at Novavax AB, he served as Chief Executive Officer of Beta-Cell N.V. (Brussels, Belgium) from 2008 to 2012 and as Chief Executive Officer of Active Biotech AB (Lund, Sweden) from 1999 to 2008.

Mr. Andréasson spent a number of years in roles at Pharmacia Corporation (merged with Pfizer Inc.), including President of Pharmacia SA, France, President of KabiPharmacia International and President of Pharmacia Arzneimittel GmbH. He has extensive experience in international biotechnology companies and in the pharmaceutical industry.

OTHER CURRENT MANDATES AND FUNCTIONS

- Senior Vice President, Corporate Development for Novavax, Inc.
- Director of Cellastra Inc
- Director and Chairman of the Audit Committee of Immunicum AB

OTHER OFFICES AND POSITIONS HELD OUTSIDE THE COMPANY OVER THE PAST FIVE YEARS AND NOW TERMINATED

- Chairman of Cantargia AB
- Chairman of OIL AB

NUMBER OF SHARES HELD AS OF APRIL 30, 2022

- 1 ordinary share
- 16,250 BSA₂₀₁₇
- 15,000 BSA₂₀₁₉

REQUEST FOR ADDITIONAL DOCUMENTS AND INFORMATION

Request to be returned to:

By electronic way
legal@erytech.com

By mail
ERYTECH PHARMA
60 avenue Rockefeller
69008 Lyon



**COMBINED GENERAL
MEETING
24 JUNE 2022**

The documents and information referred to in Article R. 225-83 of the French Commercial Code can be consulted on the Company's website in the Investors/Shareholders Meeting section.

I, the undersigned,

Name or company name:

First name:

Address:

Owner of registered shares

And/or bearer shares (attach a certificate of registration in the bearer share accounts held by your financial intermediary)

requests that the documents and information concerning the General Meeting convened for Friday, June 24, 2022, as referred to in articles R. 225-81 and R. 225-83 of the French Commercial Code, be sent in the following format:

- Paper
- Electronic files to the following email address:

In: on : 2022

Signature

In accordance with article R. 225-88 of the French Commercial Code, the owners of shares may, by a single request, obtain from the Company the documents and information referred to in articles R. 225-81 and R. 225-83 of the French Commercial Code for each subsequent general meeting. If the shareholder wishes to take advantage of this option, this must be mentioned on the present request.

STATUTORY AUDITORS' REPORTS

- Report of the statutory auditors on the capital reduction
- Report of the statutory auditors on the issue of shares and various marketable securities with shareholders' preferential subscription rights maintained or waived
- Report of the statutory auditors on the capital increase reserved to members of a company savings plan
- Report of the statutory auditors on the allocation of existing or new bonus shares
- Report of the statutory auditors on the authorization to allocate stock options
- Report of the statutory auditors on the authorization to issue detachable share subscription warrants with shareholders' preferential subscription rights waived
- Supplementary report of the statutory auditors on the issue of stand-alone warrants with shareholders' preferential subscription rights waived
- Supplementary report of the statutory auditors on the issue of shares with warrants reserved for categories of investors with shareholders' preferential subscription rights waived
- Supplementary report of the statutory auditors on the issue of shares with warrants reserved for categories of investors with shareholders' preferential subscription rights waived

French versions of the statutory auditor's reports are available on the Company's website.

SPECIAL REPORTS OF THE BOARD OF DIRECTORS

The special report of the Board of Directors on the granting of bonus shares and the special report of the Board of Directors on stock options, as well as the additional reports on the implementation of the delegations of authority granted by the Combined General Meeting of June 25, 2021, and by the Combined General Meeting of June 26, 2020, are available on the Company's website, in accordance with applicable legal and regulatory provisions.



erytech

Société anonyme with a share capital of
€ 3,101,855.30

Registered office : 60 Avenue Rockefeller
69008 Lyon - France

479 560 013 RCS LYON